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ABSTRACT

REGULATION OF TOXIN SYNTHESIS BY CLOSTRIDIUM DIFFICILE
Clostridium difficile is the leading definable cause of nosocomial diarrhea
worldwide due to its virulence, multi-drug resistance, spore-forming ability, and
environmental persistence. The incidence of C. difficile infection (CDI) has been
increasing exponentially in the last decade. Virulent strains of C. difficile produce
either toxin A and/or toxin B, which are essential for the pathogenesis of this
bacterium. Current methods for diagnosing CDI are mostly qualitative tests that
detect the bacterium, the toxins, or the toxin genes. These methods do not
differentiate virulent C. difficile strains that produce active toxins from non-virulent
strains that do not produce toxins or produce inactive toxins. Based on the
knowledge that C. difficile toxins A and B cleave a substrate that is stereochemically
similar to the native substrate of the toxins, uridine diphosphoglucose, a
quantitative, cost-efficient assay, the Cdifftox activity assay, was developed to
measure C. difficile toxin activity. The concept behind the activity assay was
modified to develop a novel, rapid, sensitive, and specific assay for C. difficile toxins
in the form of a selective and differential agar plate culture medium, the Cdifftox
Plate assay (CDPA). This assay combines in a single step the specific identification
of C. difficile strains and the detection of active toxin(s). The CDPA was determined
to be extremely accurate (99.8% effective) at detecting toxin-producing strains
based on the analysis of 528 C. difficile isolates selected from 50 tissue culture
cytotoxicity assay-positive clinical stool samples. This new assay advances and
improves the culture methodology in that only C. difficile strains will grow on this
vi

medium and virulent strains producing active toxins can be differentiated from nonvirulent strains. This new method reduces the time and effort required to isolate and
confirm toxin-producing C. difficile strains and provides a clinical isolate for antibiotic
susceptibility testing and strain typing. The Cdifftox activity assay was used to
screen for inhibitors of toxin activity. Physiological levels of the common human
conjugated bile salt, taurocholate, was found to inhibit toxin A and B in vitro
activities. When co-incubated ex vivo with purified toxin B, taurocholate protected
Caco-2 colonic epithelial cells from the damaging effects of the toxin. Furthermore,
using a caspase-3 detection assay, taurocholate reduced the extent of toxin Binduced Caco-2 cell apoptosis. These results suggest that bile salts can be effective
in protecting the gut epithelium from C. difficile toxin damage, thus, the delivery of
physiologic amounts of taurocholate to the colon, where it is normally in low
concentration, could be useful in CDI treatment. These findings may help to explain
why bile rich small intestine is spared damage in CDI, while the bile salt poor colon
is vulnerable in CDI.
Toxin synthesis in C. difficile occurs during the stationary phase, but little is
known about the regulation of these toxins. It was hypothesized that C. difficile toxin
synthesis is regulated by a quorum sensing mechanism. Two lines of evidence
supported this hypothesis. First, a small (<1 KDa), diffusible, heat-stable toxininducing activity accumulates in the medium of high-density C. difficile cells. This
conditioned medium when incubated with low-density log-phase cells causes them
to produce toxin early (2-4 hrs instead of 12-16 hrs) and at elevated levels when
compared with cells grown in fresh medium. These data suggested that C. difficile
vii

cells extracellularly release an inducing molecule during growth that is able to
activate toxin synthesis prematurely and demonstrates for the first time that toxin
synthesis in C. difficile is regulated by quorum signaling. Second, this toxin-inducing
activity was partially purified from high-density stationary-phase culture supernatant
fluid by HPLC and confirmed to induce early toxin synthesis, even in C. difficile
virulent strains that over-produce the toxins. Mass spectrometry analysis of the
purified toxin-inducing fraction from HPLC revealed a cyclic compound with a mass
of 655.8 Da. It is anticipated that identification of this toxin-inducing compound will
advance our understanding of the mechanism involved in the quorum-dependent
regulation of C. difficile toxin synthesis. This finding should lead to the development
of even more sensitive tests to diagnose CDI and may lead to the discovery of
promising novel therapeutic targets that could be harnessed for the treatment C.
difficile infections.
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CHAPTER 1: THE NATURAL HISTORY OF CLOSTRIDIUM DIFFICILE AND
PATHOGENESIS

1

1.1 The History of C. difficile
Clostridium difficile was first isolated in 1935 by Hall and O’Toole (87), who
were investigating the development of normal bacterial flora in neonates. They
collected feces of new-born babies from sterile diapers, suspended the feces in
sterile water, and examined prepared slides microscopically using the Gram’s
method (84) and methylene blue staining. Primary cultures were prepared and
tested for the presence of aerobic bacteria on blood agar and eosin methylene blue
lactose agar plates. The presence of anaerobic bacilli was also tested using
dextrose broth constricted tubes and deep iron brain medium. Different bacterial
species were isolated and identified from the feces of these neonates including
various species of Streptococcus, Micrococcus, Lactobacillus, and anaerobic bacilli.
The most interesting among them was an obligate anaerobic bacillus (Fig. 1.1) that
was observed to be an actively motile, heavy-bodied rod with elongated subterminal or nearly terminal spores of about the same diameter as the rods (87). This
obligate anaerobic bacillus was associated with Kopfchenbacterien in feces from
three of the infants. Both bacteria appeared and disappeared at about the same
time under similar conditions. According to Hall and O’Toole (87), the isolation of
each of the two was complicated when both were present, but this anaerobic
bacillus was more difficult to isolate than the Kopfchenbacterien. This bacterium
was also much more difficult to study, due to its slower growth and lack of distinctive
morphological properties.
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Figure 1.1: Bacillus difficilis (now Clostridium difficile) grown for 48 hrs on a blood
agar slant under alkaline pyrogallol. The Gram stain (84) showed vegetative rods
and spores (87). Kingdom: Bacteria; Phylum: Firmicutes; Class: Clostridia; Order:
Clostridiales; Family: Clostridiaceae; Genus: Clostridium; Species: Clostridium
difficile (87).
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Based on Hall and O’Toole’s account (87), the colonies of this anaerobic bacillus
generally emerged in deep agar after 48 hrs of incubation and initially appeared
minute, flat, and opaque. After 3 days, the colonies appeared lobulated in shape
with a diameter of about 1 mm. Single colonies on blood agar slants under alkaline
pyrogallol were irregular in form, flat, and non-hemolytic.
Dextrose broth cultures of 13 isolated strains of this new anaerobic bacillus
were incubated for 48 hrs under anaerobic conditions at 37oC and subcutaneously
inoculated into guinea pigs. Following inoculation, the guinea pigs refused to eat
and exhibited moderate to marked edema on the belly, breasts, and at the site of
inoculation. Postmortem observation showed marked subcutaneous edema with or
without congestion, but with no emphysema. Smears from the subcutaneous site of
inoculation in one animal that died within 4 hrs showed numerous Gram-positive
rods, but no spores or leukocytes were observed (87). In all the animals, no
evidence of septicemia was apparent, but phagocytic leukocytes were found with
few free bacteria. A guinea pig injected with a culture filtrate died within 24 hrs,
whereas boiling of the culture filtrate for one minute completely destroyed the
toxicity. These observations indicated that the new anaerobic bacillus produced and
released soluble exotoxins into the medium. Hall and O’Toole (87) thus, named this
new anaerobic bacterium Bacillus difficilis (now called Clostridium difficile), due to
the difficulties in its isolation and culture.
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1.2 The Life Cycle of C. difficile
C. difficile exist either as actively dividing vegetative cells or as spores (Fig.1.2).
The vegetative cells are obligate anaerobes and sensitive to oxygen. In order to
survive under aerobic conditions, C. difficile forms oxygen resistant spores. Thus, C.
difficile vegetative cells excreted in feces must transform into a spore form to
survive aerobically (110). It is therefore, widely acknowledged that the C. difficile
spores initiate the infection process. The spores serve as the dissemination form of
this pathogen and germination in the gastrointestinal tract is essential for
pathogenesis. This is because only the vegetative cells cause disease.
Little is known about sporulation and germination in Clostridial species.
However, the physiological and morphological changes that occur during
sporulation in the well-studied Bacillus species are similar to that of Clostridial
species (214). Sporulation is initiated under conditions of nutrient limitation or other
unfavorable conditions, when the cells can no longer maintain vegetative growth. In
Bacillus species, signal transduction systems that control sporulation initiation have
been broadly studied and consist of extended variants of two-component signal
transduction systems (sporulation phosphorelay) (25). Sporulation-associated
sensor histidine kinases sense various environmental and cellular cues when the
cells can no longer sustain vegetative growth. As a result, a specific histidine
located

in

the

catalytic

domain

of

sensor

histidine

kinases

becomes

autophosphorylated (198). The phosphoryl group is then transferred to an aspartate
on the Spo0F response regulator and this leads to activation of the Spo0A response
regulator transcription factor via the Spo0B phosphotransferase (198). The
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phosphorylation of the active site Spo0A aspartate promotes binding to a specific
target sequence (the “0A box”) in or near the promoters of genes under Spo0A
control, leading to either activation or repression of these genes (198).
The phosphoryl groups on sensor kinases activate two-component systems and
phosphorelays. Sensor kinases generally consist of an N-terminal signal input
domain and a catalytic C-terminal kinase domain containing the dimerization and
histidine phosphotransfer sub-domain and an ATP binding sub-domain (25, 198).
The Spo0F in the sporulation phosphorelay can be phosphorylated by multiple
sensor kinases (199). In B. subtilis, there are five sensor kinases, KinA to KinE, with
conserved active sites that influence sporulation (108). One sensor kinase is
normally responsive to a single specific signal ligand; hence, incorporating several
kinases increases the variety of the signals that can be sensed and allows various
different signals to influence Spo0A activation.
In Bacillus and Clostridium species, Spo0A is highly conserved (214). The
regions upstream of genes most likely controlled by Spo0A in Clostridia contain “0A
boxes”, suggesting that the mechanism of Spo0A-mediated gene control is similar
to that of Bacillus. In Clostridium and Bacillus species, the most important residues
of Spo0A that mediate interaction with the nucleotides of the “0A box” are highly
conserved (235). However, protein sequence homology analysis indicates that the
genomes of sequenced Clostridium species do not appear to encode homologues
of Spo0F and Spo0B (199).
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Figure 1.2: The life cycle of C. difficile. This bacterium grows anaerobically as
vegetative rods. When faced with an unfavorable condition or when efforts to
maintain vegetative growth fail, it forms spores. The spores survive the unfavorable
condition and germinate when favorable conditions return.
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The general consensus has been that the sporulation initiation pathway in
Clostridium species does not involve a multi-component phosphorelay, but utilizes a
two-component system to sense signals via sporulation-associated sensor kinases
that phosphorylate Spo0A directly (200, 229).
Activated Spo0A regulates several post-exponential phase phenomena (214).
To sustain their pathogenic lifestyle, bacterial spore-formers appear to have
evolved to allow Spo0A to control virulence as well as survival responses (200). For
instance, sporulation and toxin production in Clostridium perfringens involves
Spo0A, which binds to the putative “OA box” upstream of the Cpe cytotoxin (100).
To date, no conclusive evidence exists that links sporulation and toxin
production in C. difficile. Furthermore, many reports describing direct correlations
between toxin production, sporulation, and stationary-phase events (57, 114, 117)
have been subsequently disputed by other reports demonstrating negative
correlations or no link at all (3, 118). These ambiguities have been made difficult by
differences in the strains and the growth media used in these studies, as well as the
lack of effective C. difficile genetic tools to generate mutants in key genes to enable
definite analysis of the pathways involved.
Upon C. difficile sporulation initiation, an asymmetrically placed division septum
is formed that divides the cell into two unequal compartments (the mother cell and a
forespore). Each of these two compartments contains one copy of the chromosome.
The larger, mother cell compartment engulfs the forespore leading to maturation
(95). The process of maturation involves addition of a peptidoglycan cortex and
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several layers of proteins that coat around the forespore. The mother cell finally
lyses and the spore is released into the environment (92).
The spore is metabolically dormant when released from the mother cell, but is
resistant to various harsh environmental conditions, such as high temperature,
oxygen, pH, alcohols, etc. Under suitable conditions, the spores germinate and
grow as vegetative cells. Germination in B. subtilis can be artificially induced by
different compounds such as L-alanine or a mixture of asparagine, glucose,
fructose, and potassium ions (195). The B. subtilis receptors that have been
identified to be involved in sensing these environmental signals are GerA, GerB,
and GerK (105). A large amount of calcium dipicolinate is released subsequent to
sensing of the germinant, leading to hydration of the core, degradation of the cortex,
and resumption of metabolism (191). Homologs of GerA, GerB, and GerK have
been identified in many Bacillus and Clostridial species except C. difficile. This
suggests that C. difficile spores respond to a different kind of environmental signal
for germination (163, 190).
In C. difficile, germination and outgrowth of the spores have not been well
studied due to the absence of good genetic tools. Cholate derivatives of bile salts,
such as taurocholate and the amino acid glycine, act as co-germinants of C. difficile
spores (195) and improve the germination of C. difficile spores from environmental
surfaces and stool samples (17, 223). Lysozyme and thioglycolate also improve the
colony formation of C. difficile spores (115, 227). Unfortunately, the mechanism by
which these molecules stimulate germination of C. difficile spores is unknown. The
formation of spores by C. difficile is a significant impediment in overcoming hospital9

acquired C. difficile-associated diseases and recurrence. The spores contribute to
the survival of this bacterium after treatment of surfaces with antiseptics and
antibiotic therapy, which disrupts the colonic microflora and precipitates C. difficile
infection, colonization, and overgrowth in the intestinal tract (220).

1.3 Epidemiology of C. difficile Infection
The incidence of C. difficile infection (CDI) in acute care hospitals in the United
States during the early 1990s was maintained at stable rate of 30 to 40 cases per
100,000 population (143). By 2001, the incidence of CDI had risen to almost 50 per
100,000 population. The incidence rate in 2005 (84 per 100,000) was almost triple
that of 1996 (31 per 100,000) with concomitant increases in the severity and fatality
of this infection (132, 166). Currently, the number of cases of CDI in hospitals in the
United States exceeds 250,000 per year (over 80 cases per 100,000) (226, 237),
with the total cost of treatment estimated between 1 billion and 3.2 billion U.S.
dollars annually (124, 160). The number of cases occurring in the community and
non-hospital healthcare facilities appears to make CDI the most common form of
bacterial diarrhea in the U.S. Morbidity and mortality resulting from CDI in recent
years have increased significantly as a result of changes in the virulence of the
causative strains, the expanding number of the elderly and immunocompromised in
the population, and antibiotic usage patterns (143, 160, 177, 237). As a result, C.
difficile has been identified as the causative organism associated with 10-25% of
the cases of antibiotic-associated diarrhea, 50-75% of the cases of antibioticassociated colitis, and 90-100% of the cases of pseudomembranous colitis (13, 61).
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C. difficile cells overpopulate the human gastrointestinal tract after the normal
gut microflora has been reduced by antibiotic therapy. Thus, antibiotic therapy can
be considered the most significant risk factor for developing CDI (14). It appears
that the antibiotic therapy allows C. difficile to overcome the normal gut microbiota
colonization resistance mechanisms against CDI, which include occupying the
space required for C. difficile proliferation, direct impairment of C. difficile growth or
germination, siphoning nutrients or germinants from C. difficile, and shaping the
host innate and adaptive immune responses. CDI predominantly affects the elderly
and immunocompromised patients in hospitals and nursing homes (143, 166). CDI
is the most frequent cause of morbidity and mortality among elderly hospitalized
patients (194). Nevertheless, other populations are also at risk of the infection, such
as young and healthy individuals who have not undergone antimicrobial therapy or
were not exposed to a health care environment. Severe CDI that results in either
death or colectomy has also been described in young women (156).
Asymptomatic carriage of C. difficile in children is estimated to be about 50% or
higher (129). Interestingly, infants have been reported to have high levels of
toxigenic C. difficile and toxins in their stools, but present no clinical symptoms (4,
18, 38). Although, it is not known why neonates are unusually refractory to CDI,
several theories have been proposed. First, the membrane receptors required for
toxin binding in the colon may be absent in neonates. Secondly, mucins directly
inactivate the C. difficile toxins (74). Third, the thick layer of colonic mucus in
neonates may mask the toxin receptors. Fourth, the intestinal epithelial cells in
neonates have reduced sensitivity to intoxication than adult cells, and this may
11

contribute to the asymptomatic carriage (33). In fact, infant hamsters are also
insensitive to CDI (135, 183).
The emergence of hypervirulent high toxin producing strains of C. difficile has
contributed to the increasing incidence of CDI. McDonald, et al. (143, 222)
examined various C. difficile isolates collected from eight health care facilities in six
states (Illinois, Pennsylvania, Maine, Georgia, New Jersey, and Oregon) during CDI
outbreaks between 2000 and 2003. A single strain was reported to account for half
of the isolates from five of the facilities (143). Moreover, 82% of the stool samples
from another outbreak in Quebec, Canada were positive for the same strain (143).
In the 1980s, this epidemic strain was initially identified by restriction endonuclease
analysis and named BI, but it is currently referred to as North American Pulsed Field
Type 1 (NAP1) and PCR ribotype 027 (i.e., BI/NAP1/027, or NAP1/027) (143). The
unique characteristics of this virulent NAP1/027 strain are increased toxins A and B
production, fluoroquinolone resistance, and production of the binary toxin. Also,
high-level of gatifloxacin and moxifloxacin resistance has been reported in recent
isolates, but not in the original NAP1 strains. Resistant strains may have a
competitive advantage in the hospital environment where fluoroquinolone use is
widespread (165).

1.4 The C. difficile Pathogenicity Island
The essential C. difficile virulence factors are two large toxins that are
chromosomally encoded by the genes tcdA (toxin A) and tcdB (toxin B). The toxin
genes together with the genes that encode the proteins TcdR, TcdE, and TcdC lie
12

within a 19.6 kb pathogenicity locus (Fig. 1.3) in the C. difficile genome (21, 89).
TcdA (308 kDa) is known to function as an enterotoxin causing gastrointestinal
damage, whereas TcdB (269 kDa) is a highly potent cytotoxin (138).
The tcdR gene, which lies upstream of tcdB in the pathogenicity locus, encodes
an RNA polymerase sigma factor that regulates transcription from the toxin
promoters and from its own promoter (140, 141). TcdR is homologous to
transcriptional activators of several Clostridium species and families of RNA
polymerase sigma factors found in many organisms (140, 149). Proteins that have
been found in other pathogenic Clostridia similar to TcdR include the sigma factors
that control the tetanus neurotoxins (TetR) in Clostridium tetani, botulinum toxin
(BotR) in Clostridium botulinum, and UV-inducible bacteriocin (UviA) in Clostridium
perfringens (56, 176). The first evidence for the role of TcdR in C. difficile toxin
regulation was reported by Moncrief (149) and his co-workers using E. coli as a
surrogate host. These results were supported by similar experiments using C.
perfringens as a surrogate host (140) and later in C. difficile (141). Biochemical and
genetic evidence suggest that the role of TcdR is indispensable for initiation of
transcription from the tcdA and tcdB promoters (140). Furthermore, the expression
of TcdR and the toxin genes are both influenced in parallel by the growth phase,
growth temperature, and the composition of the growth medium (119). The same
expression pattern is observed for all the genes in the pathogenicity locus except
tcdC, which is highly expressed during the rapid exponential growth phase and less
expressed during the stationary phase (103).
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Figure 1.3: The pathogenicity locus of C. difficile. The tcdA and tcdB genes encode
toxins A and B, respectively. The tcdR gene encodes a sigma factor that controls
the transcription of the toxin genes, whereas the tcdC encodes a protein has been
proposed to play a negative role in toxin gene regulation by antagonizing TcdR.
TcdE codes for a protein similar to holin, that is suggested to have a role in the
release of the toxins. The exact role of TcdE and the mechanism of TcdC-mediated
repression of toxin synthesis are unclear.
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Genetic and biochemical evidence suggest that TcdC negatively regulates toxin
production by disrupting the capability of TcdR-containing RNA polymerase to
recognize the tcdA and tcdB promoters (140, 141). Thus, it has been proposed that
tcdC encodes a negative regulator of toxin production (103) and this concept has
been supported by qualitative functional genetics and in vitro protein interaction
studies (30, 142). Evidence to support this hypothesis includes the inverse
transcription pattern of tcdC in relation to the toxin genes, and the emergence of
epidemic strains (NAP1/027 strains) with deletions or frame-shift mutations in the
tcdC gene that produce high toxin levels (30, 39, 103, 139, 142, 143, 222).
Moreover, all NAP1/027 isolates from the 1980s and 1990s, like those from recent
outbreaks, carry tcdC mutations (132, 143). These reports highlight the importance
of tcdC in the pathogenesis of C. difficile. However, Cartman and co-workers (32)
found no association between toxin production and the tcdC genotype when they
deleted the tcdC gene by allelic exchange. Furthermore, restoration of the Δ117
frame-shift mutation and the 18-nucleotide deletion that occur naturally in the tcdC
gene of some virulent C. difficile strains such as R20291 did not alter toxin
production (32). This suggests that C. difficile toxin production is controlled by a
complex mechanism probably involving many different factors.
Between the toxin genes is a small open reading frame, tcdE, which encodes a
putative holin, a protein whose activity is thought to allow the release of the toxins
from the cell (205). The tcdE open reading frame encodes a small, hydrophobic
protein with 166 amino acids comprising a short hydrophilic stretch at the Nterminus and a series of charged residues at the C-terminus (205). TcdE is
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predicted to contain three transmembrane domains with structural features and a
primary sequence similar to class I holins. Holins are small membrane proteins
encoded by double-stranded DNA phages required for lysis of host cells following
completion of intracellular phage development (221, 233). Holins oligomerize in the
plasma membrane of the host cell forming a disruptive lesion, which enables the
transport of prophage-encoded endolysin (a muralytic enzyme) across the
membrane (47-49). The prophage-encoded endolysin hydrolyzes the murein of the
host cell leading to cell lysis and release of the phage particles. Even though, most
holins are associated with terminal lysis of phage-infected bacteria, some holin-like
proteins are known to be involved in the release of proteins from uninfected bacteria
(47-49).
TcdE was initially suggested to play a role in the secretion of C. difficile toxins
due to its homology to holins. Govind and Dupuy (81) have demonstrated
empirically that TcdE is required for efficient secretion of the C. difficile toxins and
facilitates release of toxins without inducing cell lysis or general membrane
permeability. On the other hand, Olling et al. (162) insertionally inactivated the tcdE
gene and observed no delay or inhibition of toxin release. Olling, et al. (162) further
stated that inactivation of TcdE did not either alter the kinetics of toxin release or the
absolute level of secreted toxins A and B, suggesting that TcdE does not account
for the pathogenicity of C. difficile. Moreover, no significance difference was
observed between the wild-type and tcdE-deficient C. difficile when the secretome
was analyzed by mass spectrometry, thus, excluding the proposed secretory role of
TcdE (162). In C. difficile, tcdE encodes a 19-kDa protein but when expressed in E.
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coli, TcdE appears as a 19 and 16-kDa protein. The truncated 16-kDa protein was
associated with bacterial cell death, suggesting that TcdE does not exhibit poreforming function in C. difficile, since only the non-lytic full length 19-kDa protein is
present (162).

1.5 The Large C. difficile Toxins
The toxins A and B are the essential virulence factors in C. difficile pathogenesis
and belong to a family of the large Clostridial glucosylating toxins (73, 123, 138,
185, 219). Strains that do not produce either of these toxins are not associated with
disease (61, 219). Both toxins have similar enzymatic cleavage activities (50, 112,
113) and are cytotoxic to cultured cells; however, toxin B is 100-1,000-fold more
potent than toxin A (111, 217, 219). C. difficile toxins A and B share high amino acid
sequence identity. These toxins are structurally similar to each other (Fig. 1.4) with
an N-terminal enzymatic domain composed of a glucosyltransferase domain and an
autocatalytic

cysteine

proteinase

domain,

a

central

translocation

domain

encompassing a hydrophobic region, and a C-terminal receptor binding domain
made up of Clostridial repetitive oligopeptides (CROPs) (106, 217).
The N-terminus of the toxins harbors the glucosyltransferase activity, which is
the biologically active domain, and a domain with the conserved catalytic triad
(Asp587-His653-Cys698)

of

a

cysteine

protease,

which

mediates

toxin

autocleavage during internalization in the host cell (203).
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Figure 1.4: Structural comparison of C. difficile toxins A and B. These toxins have
three domains: an N-terminal enzymatic domain consisting of a glucosyltransferase
domain and an autocatalytic cysteine protease domain (CPD); a central
translocation domain (TMD) encompassing a hydrophobic region (HR); and a Cterminal receptor binding domain containing the Clostridial repetitive oligopeptides
(CROPs). The DXD (Asp-X-Asp) motif and a conserved tryptophan (W102) present
in the glucosyltransferase domain are involved in Mn 2+ and UDP-glucose binding.
The DXG (Asp-X-Gly) motif in the TMD region of TcdB has an aspartate protease
activity, which may be involved in toxin cleavage (203).
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The crystal structure of the TcdB glucosyltransferase domain has been determined
and the essential amino acid residues involved in the glucosyltransferase reaction
or substrate binding have been identified (179). The Asp-X-Asp (DXD) motif and a
conserved tryptophan (W102) play a role in Mn 2+ and UDP-glucose binding (179).
There is limited information concerning the transmembrane domain and its function.
The transmembrane domain comprises more than 50% of the total amino acid
content of the toxins. It also includes a hydrophobic region whose role may be for
membrane insertion.
The CROPs of the receptor binding domain has 21-, 30-, and 50- repetitive
amino acid residues. The CROPS of TcdA contains between 30 and 38 contiguous
repeats, whereas that of TcdB has between 19 and 24 repeats (85, 96). The
CROPs may be involved in the initial target cell interaction and receptor binding by
the toxins. The crystal structure of the receptor binding domain of TcdA showed a
solenoid-like structure that has been proposed to increase the surface area of
proteins and enable protein-protein or protein-carbohydrate interactions (85, 96).
TcdA has been reported to bind to the trisaccharide, Galα1-3Galβ1-4GlcNAc,
carbohydrate antigens, components in human milk, and glycosphingolipids (122,
184, 208, 213). The crystal structure of TcdA was solved in complex with the
synthetic carbohydrate, Gal-α1-3Gal-β1-4GlcNAc (85). On the contrary, a functional
α-galactosyltransferase does not exist in humans, suggesting that Gal-α1-3Gal-β14GlcNAc cannot be an intestinal receptor in human (107). The disaccharide Gal-β14GlcNAc, which is present in humans, has therefore been suggested to be part of
the host receptor (107). Little is known about the TcdB receptor, but it has been
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suggested that the TcdB receptor appears to be at the basolateral sites, whereas
the TcdA receptor is on the apical sites on the host intestinal cells (201). However,
researchers have been unsuccessful in identifying the actual host receptor for the
toxins. The interaction between the receptor binding domain of the toxins and the
host cell receptors initiates receptor-mediated endocytosis (65, 116, 213).
Some C. difficile isolates (less than 10%) including the epidemic NAP1/027
strain also produce a third toxin that is unrelated to the pathogenicity locus called
the C. difficile binary toxin (CDT) (76). This toxin is a two-component ADP
ribosyltransferase encoded by the genes cdtA (enzymatic component) and cdtB
(binding component). The role of the binary toxin in C. difficile pathogenesis is not
clear. Toxins A- and B-negative binary toxin-positive strains cause fluid
accumulation in rabbit ileal loops, but no diarrhea or death in hamster models (72).
Moreover, C. difficile strains that produce the binary toxin in the absence of toxins A
and B do not appear to cause disease (120). The production of the binary toxin by
NAP1/027 epidemic strains has renewed speculation that this toxin may act
synergistically with toxins A and B in causing severe colitis (12, 132, 143).

1.6 The Mechanism of C. difficile Toxin Entry into the Host Cell
During infection, toxins A and B are released into the intestinal lumen where
they bind to surface receptors on colonic epithelial cells via their receptor-binding
domain (Fig. 1.5). They are then internalized by the host cell by receptor-mediated
endocytosis (52, 96). The acidic environment within the endosomes activates the
cysteine protease activity of the toxins, which cleaves and releases the
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glucosyltransferase domain located at the N-terminus into the cytosol of the
mammalian

host

(58,

98,

168,

178,

186).

A

host

cofactor,

inositol

hexakisphosphate, serves as a trigger of the cysteine protease-mediated
autocatalytic cleavage of the toxins (178).
Small GTPases (8-28 kDa) are characterized by C-termini that are
polyisoprenylated, and an intrinsic ability to bind to guanine nucleotides. In addition,
they serve as molecular relays that transmit signals when bound to GTP and
discontinue signal transmission when bound to GDP (203). Small GTPases are
subdivided into the subfamilies of Rho, Rab, Ras, Ran and Arf, and Ran. The Rho
subfamily members (Rho GTPases or Rho proteins) such as RhoA, Rac1, and
Cdc42 are the major known intracellular targets of TcdA and TcdB (111).
Once in the cytosol, the glucosyltransferase effector domain of the toxins monoO-glucosylates low molecular weight GTPases of the Rho family (RhoA, Rac1, and
CDC42) using cellular uridine diphosphoglucose (UDP-glucose) as the glucose
donor (111, 112). In the GDP-bound form, Rho GTPases are inactive and associate
with guanine nucleotide dissociation inhibitors, which keep the GTPases in the
cytosol. Rho GTPases interact with different effectors to control several signaling
processes upon activation by guanine nucleotide exchange factors (203). They
regulate many host cell functions, such as epithelial barrier functions, adhesion,
phagocytosis, cytosecretion, immune cell migration, and immune cell signaling (106,
111).
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Figure 1.5: Mechanism of C. difficile toxins entry into host cells. The toxins bind to
unknown host cell receptors and are subsequently internalized by receptormediated endocytosis (178). The low pH within the endosomes stimulates the
autocatalytic cysteine protease activity of the N-terminally located enzymatic
domain, resulting in the release of the glucosyltransferase domain. The released
glucosyltransferase

inactivates

small

molecular

weight

GTPases

by

monoglucosylation (219).
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Monoglucosylation of the Rho GTPases by the toxins interrupts their normal
functions leading to various deleterious effects including massive fluid secretion,
apoptosis, cell rounding, actin cytoskeleton dysregulation, loss of tight junction
integrity, acute inflammation and necrosis of the colonic mucosa, and altered
cellular signaling (69, 98, 101, 111, 112). Cellular intoxication by the toxins also
induces the release of various immunomodulatory mediators from epithelial cells,
phagocytes, and mast cells resulting in inflammation and accumulation of
neutrophils (171, 210). The clinical manifestations of CDI are highly variable:
ranging from asymptomatic carriage, mild self-limiting diarrhea, to severe
pseudomembranous colitis.

1.7 Treatment of C. difficile Infections
Alteration of the normal flora by antibiotic therapy leads to the development of
CDI in susceptible individuals. Thus, an essential step in the treatment of CDI is the
immediate cessation of the inciting antibiotic. Treatments with concomitant
antibiotics are associated with significant prolongation of diarrhea and an increased
risk of recurrence (133, 152). Patients with the typical manifestations of CDI such as
diarrhea, abdominal pain, nausea, and vomiting with a positive diagnostic assay are
given oral metronidazole or vancomycin (155, 194). Metronidazole is preferred over
vancomycin as the first-line therapy for mild to moderately ill persons due to its
lower cost relative to vancomycin, comparable clinical effectiveness, and to prevent
the spread of vancomycin-resistant enterococci (5, 28). The recommended dosage
for metronidazole is 500 mg three times daily or 250 mg four times daily for 10 to 14
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days. Oral vancomycin is recommended at a dosage of 125 mg four times daily and
is the preferred treatment for more severe cases. Intravenous vancomycin has no
effect on C. difficile colitis since the antibiotic is not excreted significantly into the
colon.
Recurrent CDI frequently results from reinfection with the same or a different
strain of C. difficile (225). Recurrence mostly occurs within 1-3 weeks after
discontinuation of antibiotic usage. One-half of recurrent episodes appear to be
reinfections rather than relapses of infection with the original strain (11, 157),
although mixed initial infections may be present initially. Approximately 25% of the
cases of recurrence occur in patients treated with metronidazole or vancomycin (63,
145, 224). The main risk factors for recurrent CDI are severe underlying medical
disorders (weakened immune system), age (> 65 years), and the need for ongoing
therapy with concomitant antibiotics during CDI treatment (125, 152, 207). Patients
with at least one episode of recurrent C. difficile have a 45-65% chance of additional
episodes (144). The mechanism of CDI recurrence following initial infection is not
fully understood. A number of possible factors may contribute to CDI recurrence:
one, persistent spores from the initial infection that escape mechanical clearance by
peristalsis (207) and two, a weak host immune response to toxins A and B. High
serum antibody levels against toxins A and B have been observed in asymptomatic
carriers of C. difficile (126). Patients with recurrent CDI tend to have lower antibody
levels than patients with a brief, single episode of diarrhea (2, 125). Antibiotic
resistance does not appear to be a factor in recurrence.

Fidaxomicin, a drug
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recently approved by FDA for the treatment of C. difficile, has been reported to
significantly lower the recurrence rate of CDI (133).
Other non-antibiotic treatment options that have been advocated include
infusion of stools from healthy donors (1), adjunctive use of monoclonal antibodies
specific to the toxins (134), probiotics (145), and the use of non-toxigenic C. difficile
strains to out-compete the toxigenic strains.

1.8 Regulation of C. difficile Toxins A and B
Various physiological and environmental factors such as nutrient limitation, the
presence of branch-chained amino acids and biotin, and sub-inhibitory antibiotic
concentrations have been reported to influence toxin production. However, the
exact mechanism and the key players involved in the regulation of C. difficile toxins
A and B synthesis are not clear.
CodY, a universal regulator of gene expression in low G+C Gram-positive
bacteria, has been reported to repress C. difficile toxin genes expression (51).
Dineen, et al. reported that all of the five genes of the C. difficile pathogenicity locus
were derepressed when the codY gene was inactivated (51). CodY was found to
bind with high affinity to a DNA fragment containing the promoter region of the tcdR
gene. In the presence of GTP and branched-chain amino acids, binding of CodY to
the tcdR promoter region was enhanced and this suggests a link between nutrient
limitation and the expression of C. difficile toxin genes (51). Environmental stresses,
such as alteration of the oxidation-reduction potential, exposure to sub-inhibitory
concentrations of antibiotics, and extreme temperatures have also been reported to
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affect toxin production (119, 154). To date, no conclusive link has been defined
regarding these environmental factors and their effect on C. difficile toxin synthesis.
Furthermore, no specific regulatory or signaling mechanism connecting these
factors has been defined.
Transcription of the toxin genes in C. difficile has been reported to be affected
by a universal signaling molecule involved in quorum signaling (130), a mechanism
by which bacteria respond and adapt to their micro-environmental changes through
coordinated gene expression. In quorum signaling, a small diffusible signaling
molecule produced by one species of bacteria can act as an intraspecies and/or
interspecies communication signal. Gram-negative bacteria produce various types
of N-acyl-homoserine lactones (autoinducer-1[AI-1]) that are synthesized by
enzymes encoded by the luxI family of genes. Another signaling molecule termed
autoinducer-2 (AI-2), which is synthesized by enzymes encoded by the luxS family
of genes has been identified to be involved in quorum signaling in both Gramnegative and Gram-positive bacteria and mediates interspecies communication (26,
34, 228, 230). AI-2/LuxS-mediated regulation is important in controlling different
activities in a variety of bacterial species (230). C. difficile produces AI-2 that is able
to induce bioluminescence in a Vibrio harveyi reporter strain (130). AI-2-containing
cell-free supernatants from mid-log phase of C. difficile and E. coli DH5α producing
recombinant C. difficile LuxS increased the transcript levels of TcdA, TcdB, and
TcdE (130). However, Carter, et al. reported that AI-2 has no significant effect on
either the timing of toxin production or the amount of toxins produced by C. difficile
(31). Therefore, it is still not clear whether AI-2/LuxS is involved in C. difficile toxin
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production. Moreover, no other known quorum signaling system has been shown to
influence the production of these toxins.

1.9 Preliminary Observations on C. difficile Toxin Synthesis
Analysis of growth and toxin synthesis in C. difficile strain 630 revealed a
prolonged stationary phase during which the toxins are produced (Fig. 1.6). No
toxins were detected during the lag or exponential growth phases. Toxin synthesis
appeared to be delayed until stationary phase, suggesting that these toxins are not
constitutively expressed. These observations indicated that toxin synthesis in C.
difficile is regulated and uncoupled from growth. There are various physiological
processes and environmental changes that occur during the stationary phase,
which may influence toxin synthesis. Notable among these factors are the
decreasing nutrient levels, increase in cell density, and accumulation of metabolic
products or wastes. The toxins were produced during a growth phase when the cell
density was at its peak. Thus, toxin synthesis appeared to be coordinated and
delayed until high cell density. These results implied that a toxin-inducing factor may
be accumulating during growth, which reaches a threshold at stationary phase
leading to activation of toxin synthesis.
These observations led to the hypothesis that the synthesis of C. difficile
toxins A and B is cell density-dependent and involves a signaling pathway
that responds to extracellular cues for regulation.
It is important to note that the transcription of the toxin genes (tcdA and tcdB)
begins during the early stationary phase (103), usually between 10-14 hrs of
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growth. However, the toxins were detected by enzyme linked immunosorbent assay
(ELISA) during the late stationary phase, between 32-36 hrs (Fig. 1.6). This
discrepancy between detection of the tcdA and tcdB transcripts and toxins A and B
protein suggested that the ELISA assay used to detect the presence of the toxins
was probably not sensitive enough to detect the toxins during the early stationary
phase. As a result, a new functional, quantitative, and sensitive assay was
developed as part of this study, which was able to detect the toxins as expected
during the early stationary phase.

1.10 Significance of this Study
Treatment of C. difficile infection (CDI) is hampered by recurrence, multi-drug
resistance, and drugs with reduced functional activity in the colon. A large number
of C. difficile isolates are resistant to the majority of antibiotics currently used in
hospitals and outpatient settings (6, 16, 164, 193). As a result of the dwindling
number of antibiotics available to effectively clear this infection and prevent
recurrence, there is renewed interest in exploring a non-antibiotic treatment
approach to CDI. Non-antibiotic treatment options that have been proposed include,
infusion of stools from healthy donors (1), adjunctive use of monoclonal antibodies
specific to the toxins (134), probiotics (145), and the use of non-toxigenic C. difficile
strains to out-compete the toxigenic strains.
The spectrum of diseases caused by C. difficile is variable and the severity of
CDI depends on the level of toxins produced (3). This suggests that toxin production
is a critical and significant determinant of C. difficile pathogenicity.
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Figure 1.6: Growth of C. difficile in relation to toxin production. Toxin synthesis was
detected during the late stationary phase of growth. An overnight culture was diluted
1:100 with fresh brain heart infusion medium and incubated anaerobically at 37 oC.
Aliquots of the culture were taken every 4 hrs for O.D. 600 nm measurement and
toxin detection by ELISA using the Wampole C. difficile TOX A/B II assay (TechLab,
Blacksburg, VA).

29

Therefore, as the toxins play an essential role in C. difficile pathogenesis, inhibition
of either toxin synthesis or toxin activity are promising approaches to combat CDI.
Disruption of the regulatory mechanisms that control toxin synthesis and other
virulence factors, which do not affect growth, is less likely to pose a selective
pressure on the bacterium, and thus minimizes the risk of resistance development
compared to antibiotics.
The overall goal of this study was to investigate whether the synthesis of
toxins A and B in C. difficile is regulated by quorum signaling and to identify
and characterize the key players involved in this regulation. The data from
this study may provide insight into the processes that govern the synthesis of
these toxins. This may lead to the discovery of novel genes, molecules, or
pathways that could be targeted therapeutically for the treatment of C. difficile
infection.
This project began with the development of a more sensitive C. difficile toxin
activity assay needed to investigate the hypothesis stated above. Chapter 2
describes the purification of the toxins, validation of the toxin activity assay (the
Cdifftox activity assay), and the biochemical characterization of the toxin-substrate
kinetics. This new assay was modified into an agar-based version (the Cdifftox agar
plate assay) for use in the clinical isolation and diagnosis of C. difficile from stool
samples (Chapter 3). The Cdifftox activity assay was also utilized to identify an
inhibitor (taurocholate) of toxin activity. Chapter 4 describes how taurocholate
protected intestinal epithelial cells from the damaging effects of the toxins. The
development of this more sensitive and functional assay enabled various
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experiments to be conducted, which ultimately helped to confirm the hypothesis and
led to the conclusion that the C. difficile toxins A and B are regulated by quorum
signaling (Chapter 5).
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CHAPTER 2: HARNESSING THE GLUCOSYLTRANSFERASE ACTIVITIES OF
CLOSTRIDIUM DIFFICILE FOR FUNCTIONAL STUDIES OF TOXINS A AND B

Darkoh, C., H. B. Kaplan, and H. L. DuPont.
Journal of Clinical Microbiology, Dec. 2011, p. 4219–4224 Vol. 49, No. 12 00951137/11/$12.00 doi:10.1128/JCM.01033-11. Copyright © 2011, American
Society for Microbiology.
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INTRODUCTION

Currently, only one non-radioactive assay (the tissue culture cytotoxicity assay)
is available for the detection of the activities of the toxins. However, quantitative
analysis of toxin activity using this method is tedious and requires the maintenance
of a tissue-culture system, which makes it costly in terms of time and effort. In order
to investigate the regulation of the C. difficile toxins, determining the exact period
during which the toxins are produced was necessary and important. This required a
more sensitive and quantitative toxin assay, since the ELISA assay initially used
was not sensitive enough to detect the toxins during the early stationary phase. It
was also important to know whether active toxins were being released by the C.
difficile strains under the experimental conditions.
This chapter describes the development and validation of a quantitative assay
(Cdifftox activity assay) (41), developed as part of this project that enables detection
of the C. difficile toxins A and B in a culture supernatant. The method was based on
the inherent properties of these toxins to cleave p-Nitrophenyl-β-D-glucopyranoside
(PNPG), a chromogenic substrate with stereochemical characteristics similar to the
natural substrate of the toxins, UDP-glucose. This assay was found to be costefficient, sensitive, quantitative, and enables measurement of the cleavage activities
of toxins A and B.

2.1.1 Molecular Basis of the Cdifftox Assay
The C. difficile toxins on entering the host cell cytoplasm via receptor mediated
endocytosis recognize UDP-glucose and cleave the O-glycosidic bond between the
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UDP and glucose. The glucose liberated is attached to small molecular weight
GTPases resulting in their inactivation. This assay harnesses the ability of these
toxins to cleave O-glycosidic bonds by replacing the UDP in UDP-glucose with a
colorimetric molecule (p-Nitrophenol) that changes color when the O-glycosidic
bond is cleaved (Fig. 2.1). Under optimum conditions of temperature, pH, and
unlimited amount of the PNPG substrate, the p-Nitrophenol released is directly
proportional to the amount of the toxins present. Thus, the amount of the toxins A
and B released into the supernatant can be indirectly estimated based on the
cleavage of the colorimetric substrate.
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Figure 2.1: Molecular basis of the Cdifftox activity assay. After the toxins are
internalized

into

the

host

cell

via

receptor-mediated

endocytosis,

the

glucosyltransferase domain recognizes and cleaves UDP-glucose. The glucose
released is attached to Rho-GTPases leading to their inactivation. In this assay,
UDP-glucose was replaced by the substrate, p-Nitrophenyl-β-D-glucopyranoside.
Cleavage of this substrate results in the production of a colorimetric molecule, pnitrophenol, which can be monitored spectrophotometrically.
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MATERIALS AND METHODS

2.2.1 Bacterial Strains and Growth Conditions
Toxigenic C. difficile strains ATCC numbers 43255 (tcdA+/B+), BAA-1805
(tcdA+/B+; NAP1), 700057 (tcdA-/B+), and BAA-1382 (tcdA+/B+) were
purchased from the American Type Culture Collection (Manassas, VA).
Clinical isolates were obtained from stool samples of hospitalized patients
with antibiotic-associated diarrhea suspected to be C. difficile positive (see
below). The bacteria were grown in brain heart infusion (BHI)-based medium
(Becton Dickinson and Company, Cockeysville, MD) or on BHI-agar
containing cefoxitin (8 µg/ml) and D-cycloserine (250 µg/ml) and were
incubated anaerobically in an atmosphere of 10% H2, 5% CO2, and 85% N2
at 37°C in a Controlled Atmosphere Anaerobic Chamber (PLAS LABS,
Lansing, MI). The substrates were purchased from Biosynth International
(Itasca, IL) (41).

2.2.2 Sample Storage Condition
The clinical isolates were either stored short-term in chopped meat broth
(BD Diagnostics, NJ) at room temperature or in 15% glycerol stocks at -80°C.
The purified toxins and eluents were stored at 4°C for a maximum of one
month or until use with no loss of activity (41).
2.2.3 The Cdifftox Activity Assay
The assay consists of the Cdifftox substrate reagent composed of 5 mM
PNPG, 50 mM Tris-HCl (pH 7.4), 50 mM NaCl, and 100 µM MnCl2. The
assay was performed in Costar sterile polystyrene 96-well plates (Corning
Inc., NY) by adding to each well 200 µl of sample or culture supernatant fluid
containing the toxins and 100 µl of the reagent. The plate was incubated at
37oC for 1-4 hrs and each reaction was stopped by the addition to the well of
40 µl of 3 M Na2CO3. Cleavage of the substrate was monitored by measuring
the absorbance at 410 nm using a SPECTRA max Plus 384
spectrophotometer (Molecular Devices, Sunnyvale, CA). To identify the best
substrate for the assay, a number of substrates were evaluated including: pnitrophenyl-α-D-glucopyranoside, p-Nitrophenyl-β-D-glucopyranoside, 4-aminophenyl-α-D-glucopyranoside, 4-aminophenyl-β-D-glucopyranoside, 5-benzyloxy-3-indoxyl-β-D-glucopyranoside, 5-bromo-6-chloro-3-indoxyl-β-D-glucopyranoside, 6-bromo-2-naphthyl-α-D-glucopyranoside, 6-chloro-3-indoxyl-αD-glucopyranoside, 6-chloro-3-indoxyl-N-acetyl-beta-D-glucosaminide, and
5-bromo-4-chloro-3-indoxyl-β-D-galactopyranoside (41). P-Nitrophenyl-β-D36

glucopyranoside was selected as the substrate of choice because its
cleavage by the toxins was the most efficient and sensitive, and had the
lowest background. A molar extinction coefficient for p-nitrophenol of ε =
17700 M-1cm-1 was used in the calculations (192). One unit of toxin activity
was defined as the amount of the toxins required to cleave one micromole of
the PNPG substrate per hour under the experimental conditions (41).

2.2.4 Enzyme-linked immunosorbent assay (ELISA)
For comparison, the presence of toxins A and B in samples was also
evaluated using the Wampole C. difficile TOX A/B II assay (TechLab,
Blacksburg, VA). This assay was performed using the protocol provided by
the manufacturer (41).

2.2.5 Comparison of C. difficile Toxin Detection by Cdifftox Activity Assay and
ELISA.
An overnight culture of C. difficile strain 630 was diluted 1:100 with fresh
reduced BHI medium and incubated anaerobically at 37 oC for 48 hrs.
Aliquots of the culture were taken every 4 hrs for O.D. 600 nm measurement
and toxin testing using the Cdifftox activity assay and ELISA. For the toxin
assay, the culture was centrifuged at 10,000 rpm for 10 min and 200 µl of the
supernatant fluid was used for each assay (41).

2.2.6 Purification of C. difficile Toxins A and B
To purify the toxins, C. difficile strain (ATCC 43255) was cultured
anaerobically for 5 days at 37oC in Spectra/Por dialysis bags (50 ml) with a
molecular weight cut-off of 100 kDa (Spectrum Laboratories, Rancho
Dominguez, CA). Purification of the toxins was performed according to
established methods (146, 202, 218) with some modifications. Briefly, the
culture was centrifuged at 10,000 x g for 10 minutes at 4 oC and the resulting
supernatant was filtered through a 0.45 μm membrane filter (Millipore,
Billerica, MA). To further eliminate low molecular weight proteins, the filtered
supernatant was concentrated using a Pierce Concentrator (Thermo
Scientific, Rockford, IL) with a molecular weight cut-off of 150 kDa. The
concentrated supernatant was precipitated by the addition of ammonium
sulfate (450 g/L) and incubated overnight at 4°C with gentle stirring, and
subsequently centrifuged at 6,000 x g at 4°C for 20 min. The precipitate was
washed and dissolved in 50 mM Tris-HCl buffer (pH 7.4). The sample was
loaded onto a fast flow DEAE-Sepharose CL-6B (GE Healthcare Life
Sciences, Piscataway, NJ) anion column pre-equilibrated with buffer D (50
mM Tris-HCl [pH 7.4] containing 50 mM NaCl) at a flow rate of 2 ml/min. The
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column was washed with buffer D (approximately 350 ml) until all unbound
proteins were removed. Toxin A was eluted first with a linear gradient of NaCl
(50-250 mM) in buffer D. The elution continued for toxin B with a NaCl
gradient of 250-1000 mM in buffer D, after a washing step with 250 ml of
buffer D. The fractions (10 ml) were assayed for the presence of toxins by
incubating 200 µl with 10 mM PNPG for 3 hrs at 37oC. The toxin-positive
fractions were pooled and concentrated for further purification (41).
The pooled fractions from the DEAE-Sepharose column were further
purified by gel filtration chromatography. A 1 cm X 100 cm glass Econo
column (Bio-Rad Laboratories, Gaithersburg, MD) was packed with
Sephacryl S-300 high resolution beads (GE Healthcare Life Sciences) and
calibrated using the following standards purchased from Bio-Rad
Laboratories: vitamin B12 (1.35 kDa), myoglobin (17 kDa), ovalbumin (44
kDa), g-globulin (158 kDa), and thyroglobulin (670 kDa). The concentrated
toxins were applied to the column and eluted with buffer D at a flow rate of
0.5 ml/min. Fractions (5 ml) were assayed for the presence of the toxins
using 200 µl as described above. The purity of the purified toxins was
evaluated by electrophoresis through a 5% acrylamide: bisacrylamide PAGE
gel (187). The protein concentration of samples was determined using
Bradford assay (19) with bovine serum albumin as the standard (41).

2.2.7 Western Blot Analysis
C. difficile toxins A and B (100 µg each) were separated on 5% PAGE
gels. The proteins were transferred from the PAGE gel onto Immun-Blot
PVDF membranes (BioRad, Hercules, CA) using a Trans-Blot cell (BioRad).
The membranes were incubated with individual mouse monoclonal
antibodies specific for C. difficile toxins A or B, as the primary antibodies
(Abcam, Cambridge, MA). The WesternDot 625 Western Blot kit (Invitrogen,
Carlsbad, CA) was used to probe the membranes for the presence of each
toxin. Briefly, the membrane was incubated with Biotin-XX goat anti-mouse
IgG secondary antibody and following washing, incubated with the Qdot 625
streptavidin conjugate according to the manufacturer’s instructions. Imaging
and analysis of the treated membrane was performed using a UVP BioDoc-It
Imaging system (Upland, CA) (41).

2.2.8 Determination of Km and Vmax
A series of experiments were performed to determine the MichaelisMenten constant (Km) and maximum velocity (Vmax) for the PNPG cleavage
activities of each toxin. To determine the amount of the toxins necessary for
the experiments, different amounts of each toxin ranging from 30 µg to 120
µg were evaluated with 10 mM of PNPG as substrate. Different substrate
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amounts were also tested using 55 µg of toxin A and 100 µg of toxin B. A
graph of toxin activity as a function of time was plotted and the amount of
each toxin that gave the best linear relationship, but occurred slowly enough
for the reaction to be monitored was chosen for the assay. Based on this
analysis, 55 µg of toxin A and 100 µg of toxin B were used for the kinetics
experiments. Each experiment was repeated four times and the average
used for the analysis (41).

2.2.9 Effect of pH and Temperature on Toxin A and B Activity
The effect of pH and temperature on the activity of the toxins was
investigated to determine the optimum temperature and pH for activity. For
the pH experiment, the following buffers were used: glycine-HCl buffer (pH 23); citrate buffer (pH 4-6); Tris-HCl buffer (pH 7-10); disodium phosphatesodium hydroxide buffer (pH 11-12); and KCl-NaOH (pH 13). Each pH
experiment was initiated by incubating 100 µg of toxin A or toxin B with 10
mM of PNPG, in the appropriate buffer followed by incubation at 37oC for 4
hrs. The reaction was monitored by measuring the absorbance at 410 nm.
The effect of temperature of incubation on the PNPG cleavage activity
was tested in 1.5 ml microcentrifuge tubes using the same conditions as
described previously, except that the temperature of incubation was 4, 10,
15, 20, 25, 30, 35, 40, 45, and 50oC (41).

2.2.10 Inhibition Assay
To identify compounds that inhibit the activity of C. difficile toxins A and
B, several compounds including sodium taurocholate, dimethyl sulfoxide,
phenylmethylsulfonyl fluoride, and dimethyl formamide were tested. Different
concentrations of these agents (0, 50, 100, 200 and 300 mM) were added to
55 µg of either toxin A or toxin B in buffer D in a total reaction volume of 300
µl and incubated at 37oC for 10 minutes. After the toxin-inhibitor incubation
period, 10 mM of the PNPG substrate was added and incubated at 37 oC for
1 hr. Absorbance at 410 nm was measured and the percent inhibition was
calculated as follows (41):
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2.2.11 Application of the Cdifftox Activity Assay to Culture Supernatants from
Clinical C. difficile Isolates
Stool samples obtained from patients suspected to be infected by C.
difficile were obtained from St. Luke’s Hospital (Houston, Texas) in an IRBapproved study. Single colonies, obtained independently from each patient’s
stool sample streaked onto BHI-agar media containing cefoxitin (8 µg/ml)
and D-cycloserine (250 µg/ml), were inoculated into 10 ml of BHI medium
and incubated anaerobically at 37oC for 72 hrs resulting in an O.D. 600 nm of
about 1.3-1.4. After centrifugation at 10,000 x g for 10 min at 4 oC, 250 µl of
the supernatant was incubated with 50 µl of Cdifftox substrate reagent
containing 30 mM PNPG at 37oC for 3 hrs. The assay was quantitated
spectrophotometrically at an absorbance of 410 nm. The isolates were not
specifically typed to the strain level, but confirmed to be C. difficile based on
PCR amplification of the genes that encode the toxins (tcdA and tcdB), as
well as toxin production. Culture supernatants from 18 clinical isolates in
addition to 4 ATCC strains [BAA-1805 (tcdA+/B+; NAP1), 700057 (tcdA-/B+),
43255 (tcdA+/B+) and BAA-1382 (tcdA+/B+)] were analyzed (41).

2.2.12 Polymerase Chain Reaction Amplification of C. difficile Toxin Genes
The presence of the toxin genes (tcdA and tcdB) and the 16S rRNA gene
in the clinical isolates was confirmed by PCR amplification. Genomic DNA
was isolated from 1 ml of culture at an optical density of 0.75 at 600 nm using
the DNAEasy kit (Qiagen, Valencia, CA). Amplification was performed using
Phire Hot Start DNA Polymerase (Finnzymes, Woburn, MA). The following
primers were used: toxin A (F-5’TGATGCTAATAATGAATCTAAAATGGTAAC3’and R 5’ACCACCAGCTGCAGCCATA3’); toxin B (F-5’GTGTAGCAATGAAAGTCCAAGTTTACGC3’ and R-5’CACTTAGCTCTTTGATTGCTGCACCT3’) and 16S rRNA (F-5’ACACGGTCCAAACTCCTACG3’ and R5’AGGCGAGTTTCAGCCTACAA3’). The DNA was amplified with an initial
denaturation of 98oC for 30 s and 36 cycles of 98oC for 10 s, 62oC for 10 s
and 72oC for 10 s with a final extension of 72oC for 1 min. The PCR products
were analyzed using 1.5% agarose gel electrophoresis (41).

2.2.13 Physico-Chemical Analysis of C. difficile Toxins A and B
The ProtParam program on the ExPASy Proteomics Server (68) was
used to evaluate the physical and chemical properties of toxins A and B. This
analysis was performed computationally using the amino acid sequences
with accession numbers YP_001087137.1 and YP_001087135.1 (190) for
toxins A and B, respectively (41).
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2.2.14 Data Analysis
All the data were analyzed and plotted using GraphPad Prism version
5.02 for Windows (GraphPad Software, San Diego, CA). The nonlinear
regression method was used to calculate the Km and Vmax values. Paired ttest was used to compare the performance of the new Cdifftox Activity assay
in detecting the toxins in comparison with ELISA. In all cases, statistical
significance was defined as p<0.05 (41).
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RESULTS

2.3.1 Purification of C. difficile Toxins A and B
Clostridium difficile toxins A and B were purified seven-fold to
characterize and evaluate their substrate cleavage specificities. The native
toxins were purified from culture supernatant obtained from the toxin A- and
B- positive strain (ATCC 43255) cultured in a dialysis bag of 100 kDa
molecular weight cut-off (MWCO). The proteins in the culture supernatant
were precipitated with ammonium sulfate, resuspended, and applied to a fast
flow DEAE-Sepharose anion exchange chromatography column. After elution
with a 50 mM to 1 M NaCl step gradient, two peaks were observed by UV
detection and confirmed by Bradford assay (Fig. 2.2A). The initial narrow
peak was determined by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) to contain a protein corresponding to the
molecular weight of toxin A (308 kDa) and the second broad peak was
determined to contain a protein corresponding to toxin B (269 kDa). The
Cdifftox activity assay was used to identify fractions that contained PNPG
cleavage activity. The assay revealed two toxin-positive fractions that
corresponded to the two protein peaks observed (Fig. 2.2A). The antibodybased ELISA assay, which is immuno-reactively specific for both toxins A
and B, identified the presence of toxins A and B in the PNPG active fractions
(Fig. 2.2B). Specifically, all of the fractions that tested positive using the
Cdifftox activity assay also tested positive using the ELISA assay, and all of
the fractions that were negative for the Cdifftox activity assay were also
negative using the ELISA assay. These results indicated that the Cdifftox
activity assay detects the activities of C. difficile toxins A and B (41).
To complete the purification of the C. difficile toxin A and B, the toxinpositive fractions eluted from the DEAE-Sepharose column were pooled,
concentrated using a filter with a 150 kDa MWCO, and applied to a
Sephacryl S-300 gel filtration column. After elution with buffer D, three
predominant peaks were observed by UV detection and confirmed by the
Bradford protein assay (Fig. 2.3A). Examination of the fractions using the
Cdifftox activity assay showed that the PNPG cleavage activity was present
in two peaks of different molecular weights. The fractions with PNPG
cleavage activities were confirmed by the ELISA assay to contain the toxins
(Fig. 2. 3B). Based on the elution profiles of the gel filtration standards used,
the fractions in the first peak corresponded to toxin A (308 kDa) and those in
the second PNPG-active peak corresponded to toxin B (269 kDa) (41).
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Figure 2.2: Elution profile of the proteins in C. difficile culture supernatant
separated by DEAE-Sepharose anion exchange chromatography. Fractions (10 ml)
were examined using the Cdifftox Activity assay (A) and the antibody-based ELISA
assay (B). The Cdifftox Activity assay was performed by incubating 200 µl of each
fraction in 50 mM Tris-HCl containing 50 mM NaCl (pH 7.4) with PNPG substrate
reagent at 37oC for 4 hrs. The assay was monitored by measuring absorbance at
410 nm. The protein concentration was determined using Bradford protein assay
(BioRad). The ELISA assay was performed using the Wampole C. difficile TOX A/B
II assay (TechLab, Blacksburg, VA) (41).
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Figure 2.3: Elution profile of the pooled C. difficile toxin-positive fractions purified by
Sephacryl S-300 gel filtration chromatography. Fractions (5 ml) were examined
using the Cdifftox activity assay (A) and the antibody-based ELISA assay (B). The
Cdifftox Activity assay was performed by incubating 200 µl of each fraction in 50
mM Tris-HCl containing 50 mM NaCl (pH 7.4) with PNPG substrate reagent at 37 oC
for 4 hrs. The assay was monitored by measuring absorbance at 410 nm. The
protein concentration was determined using Bradford protein assay (BioRad). The
ELISA assay was performed using the Wampole C. difficile TOX A/B II assay
(TechLab, Blacksburg, VA) (41).
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The fractions showing sufficient toxin activity were pooled and
concentrated for further analysis by PAGE. The results from the PAGE gel
revealed a single visible band in each of the two pooled fractions
representing toxins A and B (Fig. 2.4A). This established that each toxin was
purified to homogeneity. The total PNPG substrate cleavage activities of the
toxins from each of the purification steps are shown in Table 1. The total
enzyme units of cleavage activities of the toxins were enriched by 158-fold.
The final substrate cleavage activities of the purified toxins were 0.821 U/mg
and 4.7 U/mg for toxins A and B, respectively (41).

2.3.2 Characterization of Toxin A and B Activity
To confirm that both toxins A and B cleave the PNPG substrate, Western
immunoblot analysis was performed. Single bands were observed in each of
the samples that had PNPG activity and contained either purified toxin A or B
due to their specific reactivity with monoclonal antibodies that recognize toxin
A or B, respectively (Fig. 2.4B). Moreover, toxin A-specific monoclonal
antibody did not recognize toxin B, and the antibody specific for toxin B did
not recognize toxin A. These results demonstrate that both toxins A and B
cleave the PNPG substrate. This is consistent with the reported in vivo
activity of these toxins, in that they both cleave the same cellular substrate,
UDP-glucose (41, 111-113) (41).
The effects of pH and temperature on the functional activities of the
toxins were evaluated. The pH experiments were performed using 5 different
buffers to establish a wide range of buffering capacities. Both toxins A and B
demonstrated optimal PNPG cleavage activities within a pH range of 7-9
(Fig. 2.5A). In contrast to toxin A, which showed significant activity within the
pH range of 6 to 12, toxin B displayed a more narrow range of PNPG
cleavage activity within the pH range of 7 to 10. This is consistent with the
pathophysiological environment of the colon, where C. difficile causes
disease. The pH of the colon varies from 6.4 ± 0.6 to 7.5 ± 0.4 (121). Both
toxins showed activity optima at a temperature range of 35-40oC, with toxin A
showing a broader range of activity than toxin B (Fig. 2.5B) (41).
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Table 1: Summary of C. difficile toxins A and B purification from crude culture
supernatant (41).

a

One unit of toxin activity was defined as the amount of the toxins required to cleave

one micromole of the PNPG substrate per hour under the experimental conditions.
b

Fold purification was calculated using the combined specific activities of toxins A

and B.
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Figure 2.4-A: Polyacrylamide gel electrophoresis (PAGE) analysis of C. difficile
toxins A and B purification by anion exchange and gel filtration chromatography.
Proteins (50 µg each) were separated through a 5% PAGE gel. M= ProSieve
QuadColor molecular weight marker (Lonza Rockland Inc., ME); 1= concentrated
supernatant; 2= pooled and concentrated fractions from anion exchange; 3 = pooled
and concentrated fractions from gel filtration (toxin A); 4= pooled and concentrated
fractions from gel filtration (toxin B). The arrow indicates the location of toxins in the
gel. B: Western immunoblot analysis of C. difficile toxins A and B after gel filtration
chromatography. Proteins (85 µg each) were separated by electrophoresis through
a 5% PAGE gel and transferred onto PVDF membranes. Each membrane was
probed using mouse monoclonal primary antibodies specific for toxins A or B. The
WesternDot 625 Western Blot kit (Invitrogen, Carlsbad, CA) was used for the
detection of the bound antibodies. Sup = crude culture supernatant; Tox A = Toxin
A; Tox B = Toxin B (41).
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Figure 2.5: Effect of pH (A) and temperature (B) on the PNPG cleavage activities of
toxins A and B. For the pH experiment, the Cdifftox activity assay was performed
by incubating 100 µg of toxin A or B with 10 mM PNPG at 37 oC for 4 hrs in buffers
at the various pH values shown. For the temperature experiment, the Cdifftox
activity assay was performed by incubating 100 µg of toxin A or B in 50 mM TrisHCl containing 50 mM NaCl (pH 7.4) with 10 mM PNPG at the temperatures
indicated for 4 hrs. The assay was monitored by absorbance at 410 nm. Error bars
represent standard deviation between two replicate experiments (41).
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The amino acid sequences of the toxins were analyzed using the
ProtParam program (68) to assess their physico-chemical characteristics.
Based on the ProtParam analysis, toxin A has 588 total charged residues out
of 2710 residues, of which 54% and 46% are negatively and positively
charged, respectively. Toxin B has more charged residues (597 out of a total
of 2366 residues); 66% and 34% are negatively and positively charged,
respectively. These data support the lower isoelectric point (IEP) of 4.42
estimated for toxin B compared to that of toxin A (5.51). The implication of
this lower IEP for toxin B is a wide pH range for the maintenance of its overall
negative charge at physiological pH. Toxin A is computed to be more stable
with an instability index (86) of 29.6 compared to that of 36.5 for toxin B.
However, both toxins are estimated to have relatively long in vitro half-lives
based on the N-terminal end rule (8, 77, 212) of 30 hrs. These computational
data suggest that toxin A should function in and tolerate a wider range of
physiological and environmental conditions than toxin B (41).
To better define the activities of toxins A and B, a kinetic analysis was
performed. The affinities and enzymatic cleavage abilities of each toxin for
the PNPG substrate was assessed. Initially, to determine the amount of each
toxin that cleaves the substrate at a measurable rate under the experimental
conditions, different amounts of the toxins were evaluated at constant
substrate concentration. As expected, this resulted in a dose-dependent
cleavage of the substrate with increasing toxin amounts (Fig. 2.6). Different
concentrations of the substrate were also tested at constant toxin amount.
Increasing substrate concentrations led to an increase in cleavage products
as the incubation time increased (Fig 2.7) (41).
The activity of both toxins could be fit to the Michaelis-Menten curve,
indicating a single active site reaction (Fig. 2.8). The Michaelis-Menten
constant (Km) values of the toxins for the PNPG substrate were determined
by non-linear regression to be 1.04 mM for toxin A and 0.24 mM for toxin B.
The maximum velocity (Vmax) for toxin A was 1.5 µmoles/mg/min, whereas
that for toxin B was 6.4 µmoles/mg/min. These data indicate that the affinity
of toxin B for the PNPG substrate is more than 4-fold higher than toxin A.
Moreover, the rate of cleavage of the PNPG substrate was 4.3-fold faster for
toxin B than toxin A. These results agree with assays of the relative damage
by toxins A and B to tissue culture cells, in which toxin B was found to be
more potent than toxin A (112, 217, 219) (41).
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Figure 2.6: The PNPG substrate cleavage by different amounts of toxin A (A) and
toxin B (B). Different amounts of the purified toxins were incubated with 10 mM
PNPG substrate at 37oC for 4 hrs. The cleavage of the substrate was monitored at
wavelength 410 nm.
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Figure 2.7: The PNPG substrate cleavage by 55 µg of toxin A (A) and 100 µg of
toxin B (B). Different concentrations of the PNPG substrate were incubated with
constant amount of the toxins at 37oC for 8 hrs. The cleavage of the substrate was
monitored at wavelength 410 nm.
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Figure 2.8: The Michaelis-Menten plot for the PNPG cleavage by C. difficile toxins
A and B based on non-linear regression method. For toxin A: Km = 1.04 ± 0.06 mM
and Vmax = 1.50 ± 0.03 µmoles/mg/min. For toxin B: Km = 0.24 ± 0.02 mM and
Vmax = 6.40 ± 0.12 µmoles/mg/min. Error bars represent standard deviation from
four replicate experiments (41).

52

2.3.3 C. difficile Activity Inhibition
To further characterize the toxin-substrate interactions, I sought to
identify molecules or compounds that could inhibit the activities of toxins A
and B. After testing several potential molecules (see Materials and Methods),
sodium taurocholate was observed to inhibit the activities of both toxins. The
addition of 300 mM of sodium taurocholate reduced the activities of toxins A
and B within one hour of incubation by 71% and 86%, respectively (Fig. 2.9).
Interestingly, taurocholate and phosphatidylserine (both negatively charged
lipids) have been reported to inhibit β-glucosidases in a non-competitive
manner (35, 83, 99, 167). These results support the idea that the cleavage of
the PNPG substrate is due to the glucosyltransferase/hydrolase activities of
the toxins (41).

2.3.4 Evaluation of the Period C. difficile Toxins are Synthesized

The C. difficile toxins A and B are produced and released during the stationary
phase of growth. To test the sensitivity of the new Cdifftox activity assay in
comparison with ELISA, the growth of C. difficile and toxin synthesis were
examined. C. difficile cells were monitored for growth and the culture supernatant
fluid was tested for the toxins over a 48-hr period. Growth was determined by
optical density measurement at wavelength 600 nm whereas toxin production was
determined using the new Cdifftox activity assay (41) and ELISA. The new Cdifftox
activity assay detected the toxins between 12-16 hrs of growth whereas the ELISA
test detected the toxins between 32-36 hrs (Fig. 2.10). Detection of the toxins by the
Cdifftox activity assay during the early stationary phase is consistent with the period
during which the transcription of the toxin genes occurs.
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Figure 2.9: Dose-response inhibition by sodium taurocholate of toxin A and B
PNPG cleavage activities. These experiments were performed by incubating 55 µg
of each toxin for 1 hr with the amount of sodium taurocholate indicated at 37 oC in 30
mM Tris-HCl buffer (pH 7.4) containing 50 mM NaCl, and 10 mM of the PNPG.
Error bars indicate standard deviation from three different experiments (41).
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Figure 2.10: Comparison of toxin detection by the Cdifftox activity assay and
ELISA. An overnight culture of C. difficile strain 630 was diluted 1:100 in fresh
reduced BHI medium and incubated anaerobically at 37 oC. Aliquots were taken
every 4 hrs for O.D. 600 nm measurement and toxin testing using the new Cdifftox
activity assay (red) and ELISA (purple).
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2.3.5 Analysis of Toxin Activity in C. difficile Supernatant Fluid
To evaluate the capability of this new Cdifftox activity assay to detect C.
difficile toxins A and B in culture supernatant, C. difficile strains were isolated
from clinical stool samples. Cultures were prepared from 18 independent
clinical isolates from different patients and their supernatants were tested for
toxins A and B using the Cdifftox activity and ELISA assays. All the culture
supernatants from the clinical isolates determined to be positive for the toxins
by the Cdifftox activity assay were also positive by the ELISA assay (Fig.
2.11) (41). The toxin-negative culture supernatants were negative in both
assays. Genomic DNA was isolated from each strain and PCR amplification
analysis was performed with specific primers to identify the genomes
encoding the C. difficile tcdA (toxin A) and tcdB (toxin B). The toxin genepositive isolates matched those that were toxin-positive by the Cdifftox
activity and ELISA assays (data not shown). Paired t-test analysis showed
both ELISA and Cdifftox Activity assay correlated significantly in detecting
the presence of the toxins (p = 0.001). However, there was not always a
correlation between the amount of ELISA signal and the Cdifftox activity. This
was expected as the ELISA is not quantitative, whereas the Cdifftox assay is
quantitative. Interestingly, some of the isolates that were confirmed by PCR
to encode tcdA and tcdB and tested positive with the Cdifftox activity assay,
initially tested negative with the ELISA assay. However, these isolates
became ELISA positive after longer incubation of the culture, suggesting that
the Cdifftox activity assay is more sensitive than the ELISA assay. All
together, these data illustrate that the Cdifftox activity assay is a sensitive
and reliable method to detect and assess the functional activities of C.
difficile toxins A and B in culture supernatant fluid (41).
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Figure 2.11: Comparison of clinical isolates for the presence of C. difficile toxins A
and B using the Cdifftox Activity assay and ELISA assay. Supernatant (250 µl) from
isolated strains cultured in BHI media was incubated with 10 mM of PNPG and
incubated for 3 hrs at 37oC. The assay was monitored by measuring absorbance at
410 nm. Moles of glucose released was calculated using a molar extinction
coefficient for p-nitrophenol of ε = 17700 M-1cm-1 (192). ATCC strains: 1805 = BAA1805 (tcdA+/B+; NAP1), 057= 700057 (tcdA-/B+), 432= 43255 (tcdA+/B+), 630=
BAA-1382 (tcdA+/B+), Clinical isolates: S1-S14= Culture supernatant from
independent clinical isolates obtained from different patients that were tcdA+ /tcdB+;
C1-C4= Culture supernatant from independent clinical isolates that were tcdA-/tcdB. Error bars represent the standard deviation between two replicate experiments.
Paired t-test analysis showed both ELISA and Cdifftox Activity assay correlated
significantly in detecting the presence of the toxins (p = 0.001).
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DISCUSSION

Current methods for diagnosing C. difficile infection are based on detection of
the organism, the toxin genes and proteins, or the effect of the cytotoxin on tissue
culture cells (10, 44-46). The only method that can provide information about the
activities of the toxins is the tissue culture cytotoxicity assay. Such limitations are
problematic for diagnosis and studies of these toxins. The necessity for a more
sensitive assay to enable detection of the toxins at early stationary phase led to the
development of this cost-efficient, sensitive, and reliable assay designated the
Cdifftox activity assay that utilizes PNPG as a chromogenic substrate, which is
similar to the native substrate of these toxins. Perhaps as a result, the Michaelis
constants (Km) obtained for the toxins with the non-native PNPG substrate (1.04 ±
0.06 mM and 0.24 ± 0.02 mM for toxins A and B, respectively) were relatively close
to those reported for the native UDP-glucose substrate (0.14 mM and 0.18 mM for
toxin A and B, respectively) (37).
The new assay was successfully used for the purification of C. difficile toxins A
and B, and simultaneously evaluated by comparison to the antibody-based ELISA
assay. Unlike commercial ELISA-based assays that only detect the presence of a
fragment or region of the toxins, the Cdifftox activity assay detects the presence of
the toxins and quantitates their substrate cleavage activities. It is important to note
that the Cdifftox activity assay does not distinguish between toxins A and B, since
both toxins cleave PNPG and act on the same cellular substrate in vivo (50, 112,
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113). This lack of distinction is of little consequence since both toxins are
responsible for the pathogenesis of C. difficile infections (64, 123, 136).
The PNPG cleavage activities of C. difficile toxins A and B was inhibited by
sodium taurocholate in a dose-dependent manner (Fig. 2.9). Taurocholate, which is
one of the major bile acids found in humans (55, 150), is formed and secreted into
the lumen of the small intestine by conjugation of cholic acid with taurine. The total
bile acid concentration in the small intestine varies depending on diet and other
metabolic conditions (55, 159, 169). However, only about 2-5% of the bile acids
secreted in normal humans enter the colon because the majority of the bile acids
are reabsorbed in the ileum (55, 60). The finding of inhibition of the C. difficile toxins
by a major bile acid may explain why the pathology of C. difficile infection is almost
exclusively restricted to the bile acid-poor colon with relative sparing of the bile-rich
small bowel.
Sodium taurocholate is known to non-competitively inhibit mammalian βglucosidases (35, 83, 99, 167). These enzymes, including glucosyltransferases,
belong to a large family of enzymes that mediate a wide variety of functions such as
carbohydrate biosynthesis, metabolites storage, and cellular signaling (27).
Glycosyltransferases transfer a monosaccharide from an activated nucleotide sugar
donor to specific sugar residues, proteins, lipids, DNA or small molecule acceptors.
This transfer may occur either by inversion or retention of the configuration of the
anomeric carbon (22, 175). Inhibition of toxin A and B activities by a molecule that
also inhibits glucosidases suggest that the cleavage of the PNPG substrate utilized
in the Cdifftox activity assay is due to the glucosyltransferase activities of the toxins.
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However, further confirmatory experiments are planned to test the activity of the
toxins A and B glucosyltransferase domains. The use of the glucosyltransferase
activities of the A and B toxins to identify toxigenic C. difficile is unique and has not
previously been reported.
The Cdifftox activity assay was modified into an agar-based method for
detection of toxin-producing C. difficile strains from stool samples. The Chapter that
follows describes how this was done and the validation experiments performed,
which demonstrated that the modified agar-based method may be useful for clinical
detection and diagnosis of C. difficile directly from stool.
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CHAPTER 3: A NOVEL APPROACH FOR DETECTION OF TOXIGENIC
CLOSTRIDIUM DIFFICILE FROM STOOL SAMPLES

Darkoh, C., H. L. DuPont, and H. B. Kaplan.
Journal of Clinical Microbiology, Aug. 2011, p. 2933–2941 Vol. 49, No. 8
0095-1137/11/$12.00 doi:10.1128/JCM.00037-11, Copyright © 2011, American
Society for Microbiology.
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INTRODUCTION

Clinical identification of C. difficile in fecal samples relies on a combination of at
least two techniques, which may include culture isolation, PCR detection of the
toxin-encoding genes, the tissue culture cytotoxicity assay, and immunological
detection of the toxins (ELISA). Culture isolation is normally performed on the
commercially available media, cycloserine-cefoxitin fructose agar (CCFA), which is
selective but does not differentiate the toxin-producing strains from strains that do
not produce the toxins. As a result, a second method is required to determine if a
strain is pathogenic. PCR assays are gaining popularity for the diagnosis of CDI
because of their high sensitivity in detecting the toxin-encoding genes. The tissue
culture cytotoxicity method is not as sensitive as culture isolation combined with
toxin testing (44, 70), although it is considered by some laboratories as the gold
standard. Other approaches include the glutamate dehydrogenase screening assay
(180, 211), and automated PCR-based methods such as Cepheid Xpert Clostridium
difficile Epi Assay (7, 209), and the loop-mediated isothermal amplification test
(158). However, these methods do not isolate and differentiate toxigenic from nontoxigenic strains of C. difficile.
This Chapter describes the development of a single-step selective and
differential agar-based assay, the Cdifftox Plate assay (CDPA), which enables
identification of toxin-producing C. difficile without the need for additional toxinconfirmatory tests. This assay was based on the finding, as described in Chapter 2,
that the A and B toxins of C. difficile cleave a chromogenic substrate that has
stereochemical characteristics similar to their natural substrate, UDP-glucose.
62

MATERIALS AND METHODS

3.2.1 Bacterial Strains and Growth Conditions
The toxigenic C. difficile strains ATCC 43255 (tcdA+/B+), ATCC BAA1382 (tcdA+/B+), ATCC 700057 (tcdA-/B+), and the hypervirulent strain,
ATCC BAA1805 (tcdA+/B+) were purchased from the American Type Culture
Collection (Manassas, VA). Brain Heart Infusion (BHI) medium was
purchased from Becton Dickinson (Cockeysville, MD). The substrates: 5bromo-4-chloro-3-indolyl-α-D-glucopyranoside, 5-bromo-4-chloro-3-indolyl-βD-glucopyranoside, 5-bromo-4-chloro-3-indolyl-α-D-galactopyranoside, 5-bromo-4-chloro-3-indoxyl-β-D-galactopyranoside, 5-bromo-4-chloro-3-indoxylphosphate, 5-bromo-4-chloro-3-indoxyl butyrate, 5-bromo-4-chloro-3-indoxylβ-D-xylopyranoside, 5-bromo-4-chloro-3-indoxyl palmitate, 5-bromo-4-chloro3-indoxyl-α-D-maltotrioside, 5-bromo-4-chloro-3-indoxyl-β-D-glucuronic acid,
5-bromo-4-chloro-3-indoxyl caprylate , and 5-bromo-4-chloro-3-indoxyl choline phosphate were purchased from Biosynth International (Itasca, IL). The
liquid or plate cultures were incubated anaerobically in an atmosphere of
10% H2, 5% CO2, and 85% N2 at 37°C in a Controlled Atmosphere Anaerobic
Chamber (PLAS LABS, Lansing, MI) (40).

3.2.2 Sample Storage Conditions
The clinical isolates were either stored short-term (less than 1 month) in
chopped meat broth (BD Diagnostics, Franklin Lakes, NJ) at room
temperature or long-term in 15% glycerol stocks at -80°C. The culture
supernatants were stored at 4°C for a maximum of 2 weeks with no loss of
toxin activity (40).

3.2.3 Clinical Stool Samples
The clinical stool samples were obtained from a study approved by the
Institutional Review Boards of The University of Texas Health Science
Center at Houston and St. Luke’s Episcopal Hospital (Houston, Texas). All of
the participating patients or their legal guardians provided written informed
consent upon admission to the hospital. All the stool samples used were
tissue culture cytotoxicity assay-positive, as determined by the Medical
Microbiology Laboratory at the St. Luke’s Episcopal Hospital (40).
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3.2.4 Cdifftox Plate Assay Medium
This agar-based culture medium was developed to be selective for
growth of C. difficile and differential, in that it simultaneously identifies
colonies producing active toxins A and/or B, while inhibiting the growth of
non-C. difficile colonies. The following components were chosen to compose
this new Cdifftox Plate assay (CDPA) medium (per liter): BHI (6 g), peptic
digest of animal tissue (6 g), pancreatic digest of gelatin (14.5 g), NaCl (5 g),
dextrose (3 g), anhydrous Na2HPO4 (2.5 g), sodium taurocholate (0.1%)
(Sigma-Aldrich, St. Louis, MO), D-cycloserine (300 mg) and cefoxitin (8.5
mg) (Fisher Scientific, Pittsburgh, PA), 5-bromo-4-chloro-3-indolyl-β-Dgalactopyranoside (150 mg), 0.5 mM glycine, 4-methylphenol (0.025%),
defibrinated Horse blood (6%), and agar (12 g). Alternatively, BHI (6 g),
peptic digest of animal tissue (6 g), pancreatic digest of gelatin (14.5 g), NaCl
(5 g), dextrose (3 g), anhydrous Na2HPO4 (2.5 g) can be replaced with 37 g
of BBL Brain Heart Infusion medium (BD Diagnostic Systems, Franklin
Lakes, NJ) (40).

3.2.5 Cdifftox Plate Assay
For the Cdifftox Plate assay, each stool sample was streaked directly
onto two CDPA plates using a sterile loop. The plates were incubated
anaerobically for 24-72 hr at 37oC, until colonies appeared and then the
plates were exposed to air at room temperature for at least 30 min to allow
the chromogenic reaction to complete. The assay was initially tested using
the well-characterized toxin overproducing C. difficile strain ATCC 43255
(tcdA+ tcdB+) and the hypervirulent strain ATCC BAA-1805 (tcdA+ tcdB+),
along with two strains that produce less toxins, ATCC BAA-1382 (tcdA+
tcdB+) and ATCC 700057 (tcdA- tcdB+). The presumptive active toxinproducing C. difficile colonies appeared blue, while non-toxin producers
remained pale white. The blue colonies were phenotypically classified as
Tox+ (presumably tcdA+ and/or tcdB+), whereas the pale white colonies were
denoted Tox- (presumably tcdA- and tcdB- or mutants with genetic alterations
that affect toxin production or activity) (40).

3.2.6 Isolation and PCR Identification of Toxin-Producing C. difficile Strains
A total of 528 single colonies consisting of 486 Tox+ and 42 Tox- colonies
were selected from the CDPA plates for further analysis. These colonies
represented a total of 10-12 independent isolates from each stool sample.
When possible eight Tox+ and two Tox- colonies were selected from each
sample. The presence of the toxin-encoding genes (tcdA or tcdB) in the
genomes of the presumptive Tox+ and Tox- isolates was examined by PCR
amplification of a portion of each of these genes. A portion of the 16S
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ribosomal RNA (rRNA) genes was also amplified. These reactions were
performed by first isolating genomic DNA from 1 ml of an overnight culture of
each isolated colony using the DNeasy Blood and Tissue Kit (Qiagen,
Germantown, MD). Amplification was performed using Phire Hot Start DNA
Polymerase II Kit (Finnzymes, Woburn, MA). The following primers were
used: toxin A (F- 5’TGATGCTAATAATGAATCTAAAATGGTAAC3’and R5’ACCACCAGCTGCAGCCATA3’); toxin B (F-5’GTGTAGCAATGAAAGTC
CAAGTTTACGC3’ and R-5’CACTTAGCTCTTTGATTGCTGCACCT3’) and
16S rRNA (F-5’ACACGGTCCAAACTCCTACG3’ and R-5’AGGCGAGTTTCAGCCTACAA3’). The DNA was amplified with an initial denaturation of 98 oC
for 30 sec followed by 36 cycles of 98 oC for 10 sec, 60oC for 10 sec and
72oC for 10 sec, with a final extension of 72oC for 1 min (40).

3.2.7 Toxin Assays
Preparation of Culture Supernatants from the Tox+ and Tox- Clinical
Isolates
Single colonies (486 Tox+ and 42 Tox-) were inoculated into 10 ml of BHI
medium and incubated anaerobically at 37 oC for 72 hrs resulting in an O.D.
600 nm of about 1.3-1.4. After centrifugation at 10,000 x g for 10 min to
remove the cells, the culture supernatants were collected and stored at 4 oC
until use (40).
ELISA Assay: The presence of toxins A and/or B in the culture supernatants
from the isolates was evaluated using the Wampole C. difficile TOX A/B II Kit
(TechLab, Blacksburg, VA). This was performed according to the protocol
provided by the manufacturer (40).
Cdifftox Activity Assay: The activities of toxin A and/or toxin B produced by
the C. difficile isolates were measured using the Cdifftox activity assay (41),
described in Chapter 2. Briefly, this assay quantitatively measures the activity
of toxins A and B based on the inherent properties of these toxins to cleave
p-Nitrophenyl-β-D-glucopyranoside, a chromogenic substrate with stereochemical characteristics similar to the natural substrate of the toxins, UDPglucose. The assay was performed on 250 µl of each sample supernatant
fluid to which 50 µl of the substrate reagent (30 mM p-Nitrophenyl-β-Dglucopyranoside, 50 mM Tris-HCl, (pH 7.4), 50 mM NaCl, and 100 µM
MnCl2) was added in a Costar sterile polystyrene 96-well plate (Corning Inc.,
NY). It was incubated at 37oC for 1-4 hrs. Cleavage of the substrate was
monitored by measuring the absorbance at 410 nm using a SPECTRA max
Plus 384 spectrophotometer (Molecular Devices, Sunnyvale, CA). A molar
extinction coefficient for p-nitrophenol of ε = 17700 M-1cm-1 was used in the
calculations (192) (40).
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3.2.8 Evaluation of Non-C. difficile Bacteria on the Cdifftox Plate Assay
The growth of non-C. difficile bacteria on the CDPA medium under the
standard conditions used for the stool samples was examined. The following
strains were tested (asterisks indicate Gram-positive strains): Alcaligenes
faecalis, Bacteroides fragilis, B. thetaiotaomicron, B. uniformis,
Bifidobacterium adolescentis*, Campylobacter jejuni, C. perfringens*,
Enterobacter cloacae, Enterococcus faecalis*, enteropathogenic Escherichia
coli, enterotoxigenic E. coli H10407, Eubacterium lentum*, Lactobacillus*
spp, Parabacteroides distasonis, Peptostreptococcus anaerobius*,
Plesiomonas shigelloides, Prevotella melaninogenica, Proteus mirabilis, P.
vulgaris, Salmonella enteritica, S. typhimurium, Shigella flexneri, S. sonnei,
Staphylococcus aureus*, Vibrio alginolyticus, V. parahaemolyticus, and
Yersinia enterocolitica. Single colonies of these bacteria were selected from
agar plates and cultured in 10 ml of appropriate broth media. Pure broth
cultures of each of these strains were spread directly on the CDPA plates
using a sterile loop and incubated as described above (40).

3.2.9 Growth of C. difficile on Cycloserine-Cefoxitin Fructose Agar and BHIAgar Media
The stool samples were also cultured on CCFA medium (54, 70), which
was prepared as follows per liter: proteose peptone #2 (40 g), anhydrous
Na2HPO4 (5 g), anhydrous KH2PO4 (1 g), NaCl (2 g), anhydrous MgSO4 (0.1
g), fructose (6 g), neutral red (0.003%), D-cycloserine (500 mg), cefoxitin
(15.5 mg), and agar (15 g). To test for the growth of other anaerobes present
in the stool, the samples were also cultured on BHI-agar plates without
antibiotics. All plates were incubated for 24-72 hrs under anaerobic
conditions at 37oC (40).
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RESULTS

3.3.1 Examination of Known Active Toxin-Producing C. difficile Strains Using
the Cdifftox Plate Assay
The Cdifftox Plate assay uses a novel selective and differential agarbased culture medium to specifically allow the growth of C. difficile and
simultaneously identify colonies producing active toxins A and/or B, while
inhibiting the growth of non-C. difficile colonies. The assay was initially tested
using the well-characterized toxin overproducing C. difficile strain ATCC
43255 (tcdA+ tcdB+) and the hypervirulent strain ATCC BAA-1805 (tcdA+
tcdB+), along with two strains that produce less toxins, ATCC BAA-1382
(tcdA+ tcdB+) and ATCC 700057 (tcdA- tcdB+). After 24 hrs of incubation,
colonies of these strains that produced high levels of active toxins appeared
blue (Tox+), whereas those that produced undetectable toxin levels remained
pale white (Tox-), similar to the colonies shown in Figure 3.1. By 48 hrs, all
the toxin-producing colonies were blue, indicating they produced active
toxins (40).

3.3.2 Examination of Clinical C. difficile Isolates from Stool Samples Using the
Cdifftox Plate Assay
To evaluate the ability of the new Cdifftox Plate assay to detect C. difficile
strains producing active toxins from clinical stool samples, 60 tissue culture
cytotoxicity assay-positive clinical stool samples collected at the St. Luke’s
Episcopal Hospital (Houston, Texas) were tested. A loopful of each stool
sample was spread directly onto the CDPA plates and incubated
anaerobically at 37oC for 24-72 hrs. Viable bacterial colonies were
successfully isolated from 50 of the 60 tissue culture cytotoxicity assaypositive stool samples analyzed. The percentage of colonies from the 50
stool samples that appeared Tox+ on the CDPA plates is shown in Table 2.
After 24 hrs of anaerobic incubation, Tox+ colonies were detected in 44
(88%) of the 50 CDPA culture-positive stool samples. By 48 hrs of
incubation, Tox+ colonies were detected in all (100%) of the 50 samples
CDPA culture-positive stool samples. It is noteworthy that none of the stool
samples required more than 48 hrs of incubation for the Tox + colonies to be
detected. Tox- colonies selected after 72 hrs of incubation and transferred
onto new CDPA plates remained negative in the differential plate assay,
suggesting that no further incubation was necessary after the initial 48 hr of
incubation to confirm Tox- strains (40).
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Figure 3.1: Differentiation of toxigenic and non-toxigenic strains of C. difficile using
the Cdifftox Plate assay. The stool sample was spread directly onto the plate and
incubated anaerobically at 37oC for 48 hrs. Blue colonies are toxin-producing C.
difficile (Tox+); pale white colonies are non-toxin producing C. difficile (Tox-) (40).
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To further evaluate the Cdiffitox Plate assay, 20 cytotoxicity assaynegative stool samples were tested on the CDPA plates and no colonies
grew. To confirm that toxins are not present in the 30 stool samples (10
cytotoxicity assay-positive and 20 cytotoxicity assay-negative stool samples)
that did not produce colonies on the CDPA plates, an ELISA assay was
performed on each of the 30 samples. All of the ELISA results were negative,
confirming that no detectable toxins (whole toxins or portions thereof), were
present in these 30 stool samples. These data indicate that the Cdifftox Plate
assay is accurate in discriminating stool samples that do not contain viable
C. difficile strains. Furthermore, these results demonstrate that the 10
cytotoxicity assay-positive stool samples that were ELISA-negative and did
not produce viable colonies on the CDPA plates should be considered false
positives (40).

3.3.3 PCR Amplification of C. difficile Toxin-Encoding Genes
To confirm that the Tox+ colonies isolated using the Cdifftox Plate assay
possessed the genes in their genomes that encode the toxins, a total of 528
single bacterial colonies comprised of 486 Tox+ and 42 Tox- independent
clinical isolates from the 50 CDPA culture-positive stool samples were
examined by PCR amplification. All the 528 isolates tested were positive for
the conserved region of the C. difficile 16S rRNA gene (Fig. 3.2). Of the 486
Tox+ isolates evaluated, 485 (99.8%) were positive for either tcdA and/or
tcdB. Of the 42 Tox- isolates evaluated, 31 (74%) were PCR-positive for
either tcdA and/or tcdB, whereas 11 (26%) were negative for both tcdA and
tcdB. These data indicate that all the Tox+ and Tox- isolates that were able to
grow on the CDPA plates from the stool samples were C. difficile.
Furthermore, almost 100% (99.8%) of the Tox+ strains encode the genes for
synthesis of either C. difficile toxin A and/or toxin B. Interestingly, 74% of the
42 Tox- strains selected encoded one or both of the toxin genes in their
genomes (40).
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Table 2: Detection of Tox+ colonies from 50 cytotoxicity assay-positive samples on
the Cdifftox Agar plates at different times. Clinical stool samples were streaked
directly on the CDPA plates, incubated anaerobically for 24, 48, and 72 hrs and
examined after 30 min of exposure to air (40).

PERCENT OF TOX+
COLONIES

NUMBER OF STOOL SAMPLES
24 HOURS

48 HOURS

72 HOURS

76-100%

0

31

47

51-75%

1

14

-

26-50%

5

4

2

1-25%

38

1

1

0%

6

0

0
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FIGURE 3.2: Schematic representation of the analysis of 50 cytotoxic- and CDPApositive stool samples. A. PCR was performed using the genomic DNA isolated
from the Tox+ and Tox- colonies to identify a portion of the genes that encode toxin
A (tcdA) and toxin B (tcdB). B. PCR analysis of representative Tox+ and Toxstrains. Genomic DNA was isolated from the colonies and used as template in PCR
reactions with primers specific for the genes that encode toxin A (tcdA) and toxin B
(tcdB), and a conserved region of the C. difficile ribosomal RNA (16S rRNA) gene.
‘M’ represents 1Kb marker (New England BioLabs, Ipswich, MA); lanes 1-3: tcdA
amplicons; lanes 4-6: tcdB amplicons; lanes 7-9: 16S rRNA amplicons. The PCR
products were electrophoresed through a 1% agarose gel and the DNA was
detected digitally upon exposure of the ethidium bromide-treated gel to UV light
(40).
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3.3.4 Analysis of Toxin Production and Toxin Activity by the Tox+ and ToxStrains
The Cdifftox Plate assay differentiates C. difficile strains producing active
toxins from strains producing either inactive or no toxins, based on their
ability to cleave a chromogenic substrate. To ensure that the Tox+ C. difficile
cells were able to secrete active toxins, the presence and activity of toxins in
the culture supernatants of Tox+ and Tox- isolates were evaluated. Toxin
detection using the ELISA assay was performed on culture supernatants
from three isolates of each stool sample. Toxin activity was also tested on all
these isolates using the Cdifftox activity assay (41). The results (Fig. 3.3
shows a subset of these results) reveal that all the CPDA Tox+ culture
supernatants from the clinical isolates that were positive for tcdA and/or tcdB
by PCR amplification also tested positive for the presence of toxin proteins
by ELISA, and tested positive for toxin activity by the Cdifftox Activity assay.
Remarkably, all the colonies determined by the Cdifftox Plate assay to be
Tox-, whether they encoded tcdA or tcdB in their genomes or not, were
negative for the presence and activity of the toxins in both the ELISA and
Cdifftox Activity assays. These data support the results that all but one of the
486 Tox+ colonies selected on the Cdifftox Plate assay were active toxinproducing (toxigenic) C. difficile and the 42 Tox- colonies selected were nontoxin producing (non-toxigenic) C. difficile (40).

3.3.5 Selectivity of the Cdifftox Agar Medium
To evaluate the specificity of the Cdifftox Plate assay, non-Clostridium
difficile bacteria were tested for growth on the CDPA agar under the same
culture conditions as the clinical stool samples. No viable colonies were
observed when pure cultures of the following strains were streaked on the
CDPA plates: Alcaligenes faecalis, Bacteroides fragilis, B. thetaiotaomicron,
B. uniformis, Bifidobacterium adolescentis, Campylobacter jejuni, C.
perfringens, Enterobacter cloacae, Enterococcus faecalis, enteropathogenic
Escherichia coli, enterotoxigenic E. coli H10407, Eubacterium lentum,
Lactobacillus spp, Parabacteroides distasonis, Peptostreptococcus
anaerobius, Plesiomonas shigelloides, Prevotella melaninogenica, Proteus
mirabilis, P. vulgaris, Salmonella enteritica, S. typhimurium, Shigella flexneri,
S. sonnei, Staphylococcus aureus, Vibrio alginolyticus, V. parahaemolyticus,
and Yersinia enterocolitica. These data suggest that the Cdifftox Plate assay
medium is selective against non-C. difficile bacteria (40).
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FIGURE 3.3: Analysis of C. difficile toxin production in culture supernatants of
representative Tox+ and Tox- clinical isolates and defined ATCC strains. Toxin
detection was performed by ELISA and the Cdifftox Activity Assay, as described in
the Materials and Methods. ATCC strains: 630 is historical strain BAA-1382
(tcdA+/B+), 432 represents 43255 strain (tcdA+/B+), and 1805 represents BAA1805 strain (tcdA+/B+; NAP1). Clinical isolates: T1-T14 represent Tox+; N1-N6 are
Tox- (tcdA- and tcdB-). Error bars represent the standard deviation from two
replicate experiments.
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To more directly compare bacterial growth on the CDPA medium with
CCFA medium (54), which is another C. difficile selective medium, and BHIagar, a non-selective medium, all 60 cytotoxic-positive stool samples were
spread directly onto the pre-reduced plates of CCFA- and BHI-agar media
and incubated anaerobically at 37oC for 24-72 hr. The CCFA and BHI-agar
media allowed the growth of colonies from the same 50 stool samples that
were CDPA-culture positive. Overall, approximately 15% more bacterial
colonies that appeared morphologically different grew on the CCFA-agar
plates and approximately 40% more bacterial colonies grew on the BHI-agar
plates compared to the CDPA-agar plates. It appears that the additional
colonies observed on the CCFA-agar and BHI-agar plates represent non-C.
difficile anaerobic bacteria in the stool samples (40).
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DISCUSSION

Strains of C. difficile are broadly classified as being either toxin-producing or
non-toxin producing. It has been established that only the toxin-producing strains
cause disease and that toxins A and B play critical roles in the pathogenesis of C.
difficile (123, 135-138). The alarming emergence of hypervirulent strains of C.
difficile with increased toxin production, severity of disease, and mortality (59, 78,
79, 132) emphasizes the need for a sensitive diagnostic method that can
simultaneously isolate and identify toxin-producing strains. The current available
culture methods do not differentiate toxin-producing and non-toxin-producing strains
of C. difficile. The Cdifftox Plate assay described here advances and improves the
culture approach by combining the isolation of C. difficile strains on a selective
medium with the detection of active toxins in a single step, such that only C. difficile
strains will grow on this agar and virulent strains producing active toxins can be
differentiated from non-virulent strains that do not produce active toxins and as a
result do not cause disease. This new assay drastically reduces the time and effort
required to isolate and confirm an infection resulting from toxin-producing C. difficile
strains.
This new CDPA assay was evaluated by testing 60 tissue culture cytotoxicitypositive and 20 cytotoxicity-negative clinical stool samples. After 24 hrs of
incubation, the assay detected toxin-producing C. difficile colonies in 88% (44/50) of
the CDPA culture-positive samples tested (Table 2). Toxin-producing C. difficile
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colonies were detected from 100% of the 50 CDPA culture-positive stool samples
evaluated within 48 hrs of incubation. No viable bacterial colonies grew on the
CDPA plates when the 20 cytotoxicity assay-negative, ELISA-negative stool
samples and the 10 cytotoxicity assay-positive, ELISA-negative stool samples were
tested. These results reveal the high accuracy and specificity of this method.
The Cdifftox Plate assay identifies toxin-producing C. difficile colonies by their
ability to cleave a chromogenic substrate, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, into a distinct insoluble blue product that precipitates around the toxinproducing cells. This substrate cleavage by the toxins was confirmed by the
examination of 528 independent C. difficile colonies isolated from 50 stool samples
from different patients suffering from C. difficile infection. Although, non-toxinproducing strains of C. difficile can also grow on the CDPA plates, they are
differentiated by their inability to cleave the substrate and appear as white colonies.
Furthermore, none of the non-C. difficile bacterial pathogens tested could grow on
the CDPA plates under the culture conditions used to grow C. difficile. The CDPA
plate medium appeared to be more selective than the CCFA agar (54), in that the
CCFA agar allowed the growth of morphologically different colonies from the 50
culture-positive, cytotoxicity-positive stool samples.
Surprisingly, 10 stool samples evaluated as positive by the tissue culture
cytotoxicity assay did not result in colony growth on any of the culture media utilized
(selective and non-selective) under anaerobic conditions. Furthermore, the ELISA
assay that utilizes antibodies specific for toxins A and B did not detect any toxin in
all the 10 cytotoxic-positive samples. These results suggest that the tissue culture
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cytotoxicity assay misdiagnosed 10 (16%) of the 60 samples as toxin-positive. This
could have been a result of mishandling of the samples, absence of viable bacteria
in the 10 samples, or misinterpretation of the initial cytotoxicity assay results. As a
result, we agree with others (44, 70) who suggest that it is necessary to culture a
toxin-producing C. difficile bacterium from the stool to confirm a diagnosis of an
active infection or colonization.
It is important to note that whereas almost all Tox+ colonies (99.8%) on the
CDPA plates encoded the toxin genes, 74% of the Tox- colonies also encoded the
tcdA or tcdB genes in their genomes. This suggests that the genomes of some C.
difficile strains may encode the toxin genes, but do not secrete detectable amount
of toxins. It is possible that these active proteins are not produced as a
consequence of mutations in the toxin coding sequences. It is also possible that
these toxins are not produced due to alternations in the regulatory elements
necessary for transcription, translation, or secretion. Alternatively, the bacterial cells
may not have been exposed to the necessary conditions to activate toxin gene
expression (82, 89, 90, 103, 149). Factors that have been suggested to influence
toxin production are cell density, exposure to antibiotics, phage lysogeny, growth
medium composition, and nutrient limitation (51, 82, 91, 182, 231). Furthermore, C.
difficile cells in stool samples may exist as either vegetative cells at different growth
stages or as spores. Perhaps, variations in cell physiology may explain why some
colonies became Tox+ later than others. In any case, our results indicate that this
heterogeneity did not lead to false negative interpretations of any of the samples
analyzed by the Cdifftox Plate assay.
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To our knowledge, the use of the glucosyltransferase activities of the A and B
toxins to identify toxin-producing C. difficile is unique and has not been reported in
the literature or used commercially. The Cdifftox Plate assay represents a novel
detection method with potentially improved sensitivity and efficiency compared to
current diagnostic methods.
In Chapter 2, it was demonstrated that taurocholate inhibited the substrate
cleavage of C. difficile toxins A and B. The implication of this finding was that
taurocholate-mediated inhibition of these toxins may be exploited to treat C. difficile
infections. Chapter 4 extends this finding by investigating whether taurocholate
could protect colonic epithelial cells from the damaging effects of these toxins.
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CHAPTER 4: BILE SALT INHIBITION OF HOST CELL DAMAGE BY
CLOSTRIDIUM DIFFICILE TOXINS
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INTRODUCTION

Primary bile salts (cholate and chenodeoxycholate) are biosynthesized from
cholesterol in the liver and are conjugated with either glycine or taurine prior to their
release into the gall bladder (15, 151, 181). Conjugation makes bile salts less
hydrophobic, more soluble, and prevents passive re-absorption as they traverse the
gastrointestinal tract (97). In addition to their role in fat digestion and absorption, bile
salts also inhibit bacterial overgrowth in the small intestine (104, 204), a major site
of absorption of nutrients and other metabolites. Various bacteria synthesize
hydrolases that modify conjugated bile salts by deconjugation. Further alterations
can occur through dehydroxylation, dehydrogenation, and sulfation, resulting in the
generation of secondary and tertiary bile salts (109, 131, 181, 206). These bacterial
modifications render bile salts essentially insoluble, resulting in decreased aqueous
concentrations and bacteriostatic effects. Moreover, the release of amino acids as a
result of these modifications may also act as alternative electron acceptors in this
anaerobic environment (43, 102, 215), improving bacterial growth. Bile-salt
hydrolases are produced by several genera of enteric bacteria including
Clostridium, Bifidobacterium, Bacteroides, Lactobacillus, and Enterococcus (109).
We suggest that modifications to bile salts have evolved to enable the intestinal
microflora to gain survival advantage by counteracting this host defense
mechanism.
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A large number of C. difficile isolates have shown an alarming pattern of
resistance to the majority of antibiotics currently used in hospitals and outpatient
settings (6, 16, 164, 193). As a result of the dwindling number of antibiotics
available to effectively clear this infection, there is renewed interest in exploring
non-antibiotic treatment approaches to CDI, especially in cases of recurrent CDI.
Non-antibiotic treatment options that have been reported include infusion of stools
from healthy donors (1), adjunctive use of monoclonal antibodies specific to the
toxins (134), probiotics (145), and the use of non-toxigenic C. difficile strains to outcompete the toxigenic strains. As the toxins play an essential role in C. difficile
pathogenesis, inhibition of either toxin production or toxin activity is another
promising approach.
Taurocholate, a major human conjugated bile salt, was previously reported by
our laboratory to inhibit the in vitro substrate cleavage activity of the C. difficile
toxins A and B in a dose-dependent manner (41). This Chapter demonstrates that
physiologic concentration of taurocholate protects Caco-2 colonic epithelial cells in
an ex vivo assay from the damaging effects of C. difficile toxin B. Furthermore, in a
dose-dependent manner toxin B induces production of caspase-3, a protease that
commits cells to apoptosis. However, taurocholate treatment of Caco-2 cells
reduced caspase-3 induction in the presence of lethal concentrations of toxin B.
These findings suggest that in addition to their established physiological role in
metabolism, protection of the small intestine from microbial proliferation, and
neutralization of deleterious microbial products, bile salts may be effective in
protecting the gut epithelium from C. difficile toxin damage. It is possible that
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delivery of physiologic amounts of taurocholate to the colon may be developed into
a novel treatment approach for CDI.
MATERIALS AND METHODS

4.2.1 Bacterial Strains and Growth Conditions
C. difficile strains VPI 10463 [ATCC (American Type Culture Collection) 43255
(tcdA+ tcdB+)], 630 [ATCC BAA-1382 (tcdA+ tcdB+)], 5325 [ATCC BAA-1875
(tcdA+ tcdB+)], VPI 11186 [ATCC 700057 (tcdA- tcdB+)], and the hypervirulent
strain ATCC BAA-1805 (tcdA+ tcdB+)], which all produce active toxins were
purchased from the ATCC (Manassas, VA). Brain Heart Infusion (BHI) medium was
purchased from Becton Dickinson (Cockeysville, MD). The bacteria were grown in
either liquid culture in BHI medium or on Cdifftox Agar plates (40) and incubated
anaerobically in an atmosphere of 10% H2, 5% CO2, and 85% N2 at 37°C in a
Controlled Atmosphere Anaerobic Chamber (PLAS LABS, Lansing, MI). Sodium
taurocholate and sodium cholate were purchased from Sigma-Aldrich (St. Louis,
MO). The C. difficile toxins were purified as described in Chapter 2.

4.2.2 Growth of C. difficile Strains in BHI Medium Containing Taurocholate
Overnight cultures (O.D. 600 nm= 1.4) of each strain of C. difficile were diluted
1:100 in 30 ml of fresh BHI broth medium in the presence or absence of 5 mM
taurocholate and incubated anaerobically at 37oC. Portions of the cultures were
removed every 2 hrs to monitor cell growth by optical density measurements at 600
nm. After a 48 hrs incubation period, 1.5 ml of respective cultures were centrifuged
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at 10,000 x g and the supernatants were tested for the presence of toxins A and B
using the enzyme-linked immunosorbent (ELISA)-based Wampole C. difficile TOX
A/B II assay (TechLab, Blacksburg, VA) assay. The culture supernatants were also
tested for toxin activity using the Cdifftox activity assay (41). Briefly, 250 µl of the
culture

supernatants

were

incubated

with

5

mM

of

p-Nitrophenyl-β-D-

glucopyranoside at 37oC for 4 hrs. The cleavage of the substrate by the toxins was
measured spectrophometrically at 410 nm wavelength.

4.2.3 Growth and Maintenance of Caco-2 Cells
The Caco-2 cell line (ATCC HTB-37), a human colonic epithelial cell line was
purchased from ATCC. The cells were cultured and maintained in Dulbecco’s
minimal essential medium (DMEM) containing 10% fetal bovine serum in a
humidified incubator with 5% CO2. No antibiotics were used in the preparation of the
media. Cells were grown to confluence in 24-well culture plates (Corning, Corning,
NY) in a final volume of 2 ml as described (24), prior to adding taurocholate in the
presence or absence of either C. difficile toxin A or B. Sodium cholate was used as
a control. Cells were visualized using light microscopy every 24 hrs over a 5-day
period. Cells in the different treatment groups were evaluated for morphological
changes including rounding, cytoskeleton disruption, and cell death resulting from
exposure to C. difficile toxins using an EVIS XL microscope (Advanced Microscopy
Group, Bothell, WA).
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4.2.4 Capase-3 Activity Assay
The caspase-3 assay required that a total protein lysate of Caco-2 cells was
prepared from harvested cells. First, the treated cells were removed from the 24well plates using the tip of a 1-ml pipette to scrape the attached cells from the
bottom of the wells. Then the cells were transferred to microcentrifuge tubes and
centrifuged at 6,000 x g to separate the cells from the medium. Caspase-3 detection
was performed as described by the manufacturer of the Caspase-3 Colorimetric Kit
(Invitrogen, Carlsbad, CA). Briefly, the harvested cells were lysed on ice for 10 min
using 50 µl of cell lysis buffer and centrifuged at 10,000 x g. For this assay, 75 µg of
protein was incubated with the DEVD-NA substrate reagent for 8 hrs at 37oC and
the absorbance at 410 nm was measured using the Spectramax Plus
spectrophotomer (Molecular Devices, Sunnyvale, CA). A molar extinction coefficient
for p-nitrophenol of ε = 17700 M-1cm-1 was used for the calculations (192). Total
lysate protein concentrations were determined using the Pierce BCA Protein Assay
Kit (Thermo Fisher Scientific, Inc.).

4.2.5 Data Analysis
All the data were analyzed and plotted using GraphPad Prism version 5.02 for
Windows (GraphPad Software, San Diego, California). The Student’s t-test was
used to compare differences between the samples. In all cases, statistical
significance was defined as having a P value of <0.05.
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RESULTS

4.3.1 Taurocholate and Toxin Titration Assays
The total concentration of bile salts in the human small bowel ranges from 2 mM
to 30 mM, depending on diet and other metabolic conditions (159). To determine
the amount of taurocholate that could be tolerated by the Caco-2 cells, cells were
cultured in the presence of 1-25 mM taurocholate as described in the Materials and
Methods. From this analysis, 5 mM of taurocholate was determined to be the
optimum concentration tolerated based on cell viability (data not shown). Cells
incubated with and without 5 mM taurocholate were indistinguishable over a 5-day
period (Fig. 4.1, A-B). Caco-2 cells were not viable at taurocholate concentrations
above 20 mM.
Confluent Caco-2 cells were also cultured in the presence of increasing
amounts of each toxin (0, 4, 8, 12, 16, and 24 µg) to determine the amount needed
to elicit visible cytopathic changes. Cytopathological effects were observed in cells
cultured in the presence of toxin B within 24 hrs of incubation. The cells appeared
rounded, spindle-like, detached from the plate surface, and presented with an
altered cytoskeleton; all of these phenotypes were consistent with previous reports
describing the cytopathic and cytotoxic effects of these toxins (69, 101). The
addition of toxin A resulted in mild cytopathic effects that required longer incubation
times of more than 48 hrs before cytopathic changes were observed (data not
shown). These results confirmed that toxin B is more potent than toxin A (111, 217,
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219). As a consequence, only toxin B was tested in the Caco-2 protection
experiments described.

4.3.2 Taurocholate Protects Caco-2 Cells from Toxin B-Mediated Toxicity
Taurocholate was shown previously in our laboratory to inhibit the substrate
cleavage activity of toxins A and B in vitro in a dose-dependent manner (41). To test
whether taurocholate could protect Caco-2 cells from toxin B-mediated toxicity ex
vivo, Caco-2 cells were incubated in the presence or absence of 5 mM taurocholate
(Fig. 4.1, A-B). When lethal doses of toxin B (8 µg and 16 µg) were added to Caco2 monolayers in the presence of taurocholate, no detectable cytopathic damage to
Caco-2 cells was apparent (Fig. 4.1, C-F). These data revealed that taurocholate
protected cells from toxin-mediated damage and supported our previous report
demonstrating that taurocholate inhibits toxin B activity.

4.3.3 Taurocholate Decreases C. difficile Toxin B-Mediated Induction of Host
Cell Caspase-3 Production
During C. difficile infection, apoptosis is an important downstream effect
resulting from receptor-mediated toxin endocytosis into the host cell cytoplasm and
subsequent inactivation of the host GTPases. Previous reports showed that toxin A
induces cell death in human epithelial cells ex vivo via the activation of caspases
(23, 29, 71).
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Figure 4.1: Effect of C. difficile toxin B and taurocholate on Caco-2 Cells. Confluent
Caco-2 cell monolayers were incubated with 8 and 16 µg of toxin B in the presence
or absence of 5 mM taurocholate in a total medium volume of 2 ml in 24-well plates
for 24 hrs. Images were captured using an EVIS XL microscope. Magnification 10X.
Tox B, purified toxin B; TC, taurocholate.
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Caspase-3 plays a crucial role in the apoptotic pathway by catalyzing the specific
cleavage of key apoptotic mediators essential to chromatin condensation, DNA
fragmentation, dismantling of the cell, and formation of apoptotic bodies (127, 170,
234). Figure 4.2 show that various amounts (4, 8, 12, and 24 µg) of toxin B induced
elevated levels of caspase-3 activity. To determine whether taurocholate protected
Caco-2 cells from toxin B damage by preventing apoptosis, caspase-3 activity was
assessed in taurocholate-treated and untreated cells. Crude protein lysates
prepared from Caco-2 cells cultured with various amounts of toxin B in the presence
or absence of taurocholate were tested for caspase-3 activity. No caspase-3 activity
was detected either in the absence of toxin B or in cells cultured with 5 mM
taurocholate as a sole additive. In the presence of toxin B, however, caspase-3
activity was detected in a dose-dependent manner (Fig. 4.2).
Cells treated with 4-24 µg of toxin B showed a 2.5-7.5-fold increase in caspase3 activity. In contrast, Caco-2 cells cultured in the presence of toxin B and
taurocholate had significantly (p= 0.002) reduced caspase-3 activity. The addition of
5 mM taurocholate reduced caspase-3 activity in cells treated with 4, 8, 12, and 24
µg of toxin B by 99%, 68%, 68%, and 54%, respectively. These data demonstrated
that taurocholate protected Caco-2 cells from the damaging effects of toxin B as
evidenced by the decreased levels of the pro-apoptotic protease, caspase-3.
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Figure 4.2: Effect of C. difficile toxin B and taurocholate on caspase-3 activity in
Caco-2 cells. Caco-2 cells were incubated for 48 hrs with 0, 4, 8, 12 and 24 µg of
toxin B in the presence or absence of 5 mM taurocholate. Cell monolayers were
scraped from the bottoms of wells of a 24-well plate and lysed to obtain crude
protein lysates. Crude protein lysates (75 µg) were incubated with the substrate
reagent for 8 hrs at 37oC and absorbance at 410 nm was measured. A molar
extinction coefficient for p-nitrophenol of ε = 17700 M-1cm-1 was used in the
calculations (192). The error bars represent the standard error from two different
experiments.
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4.3.4 Taurocholate Does Not Inhibit C. difficile Growth or Toxin Production
In addition to their role in fat digestion and absorption, bile salts also inhibit
bacterial overgrowth in the small intestine (104, 204), which is a major site of
nutrient and metabolite absorption. Interestingly, some enteric bacteria such as E.
coli and Salmonella produce various bile salt hydrolases capable of modifying bile
salts and rendering them non-toxic to bacteria. Analysis of the C. difficile strain 630
genome revealed the presence of a homologue of bile salt hydrolase similar to
those characterized in classic enteric bacteria. To examine whether C. difficile could
grow in the presence of the physiologic taurocholate concentration used, different
toxigenic C. difficile strains were cultured in the presence or absence of 5 mM
taurocholate. Although, some strains appeared to grow better than others in the
presence of taurocholate, none of the strains tested were negatively affected (Fig.
4.3).
To assess the effect of taurocholate on toxin production and toxin activity, an
ELISA-based assay was used to analyze toxin production whereas toxin activity
was determined using the Cdifftox activity assay (41). As shown in Figure 4.4A, the
presence of taurocholate did not affect toxin production. However, toxin activity was
significantly lower (P< 0.05) for all the strains cultured in the presence of
taurocholate compared to the activity observed in the absence of taurocholate (Fig.
4.4B).
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Figure 4.3: Growth of toxin A- and B-producing strains of C. difficile in the presence
of sodium taurocholate. Overnight cultures (O.D. 600 nm = 1.4) of each strain of C.
difficile tested were diluted 1:100 in 30 ml of fresh medium with or without 5 mM of
taurocholate (TC) and incubated anaerobically at 37 oC for 48 hrs. Portions (2 ml) of
the cultures were removed for optical density measurement at 600 nm. Strain
designations: 630, ATCC BAA-1382; 432, ATCC 43255; 1805, ATCC BAA-1805;
1875, ATCC BAA-1875. The error bars represent the standard deviation from two
different experiments.
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Figure 4.4: Effect of taurocholate on C. difficile toxin production (A) and activity (B).
Overnight cultures (O.D. 600 nm = 1.4) of each strain of C. difficile tested were
diluted 1:100 in 30 ml of fresh medium with or without 5 mM of taurocholate and
incubated anaerobically at 37oC for 48 hrs. The ELISA assay was performed using
the Wampole C. difficile TOX A/B II assay to monitor toxin production. Toxin activity
was tested using the Cdifftox activity assay (41). Strain designations: 630, ATCC
BAA-1382; 432, ATCC 43255; 1805, ATCC BAA-1805; 057, ATCC 700057; 1875,
ATCC BAA-1875. The error bars represent the standard deviation from two different
experiments.
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DISCUSSION

Treatment of CDI has been hampered by recurrent infections, multi-drug
resistance, and the lack of drug concentration or functional activity in the colon to
successfully treat CDI and prevent recurrence of the infection. As a result, there is
renewed interest in finding alternative treatments, either as stand-alone therapies or
therapies designed to augment the efficacy of currently used antibiotic regimens. An
important potential treatment approach is to inhibit the activities of toxins A and B,
which are directly responsible for intestinal damage and the subsequent
inflammation associated with CDI. An approach that targets the toxins without
affecting cell growth may be ideal since it is unlikely to impose selective pressure on
C. difficile, thereby minimizing the risk of developing resistance. In our search for
compounds that inhibit toxin activity, the Cdifftox assay was developed (41), which
uses the ability of toxins A and B to cleave a chromogenic substrate that is
stereochemically similar to their native substrate (UDP-glucose). Using this Cdifftox
assay, taurocholate was identified as a compound that inhibits the substrate
cleavage activity of these toxins (41).
In this Chapter, it was demonstrated that a physiologic concentration of
taurocholate (5 mM) was able to protect human colonic epithelial Caco-2 cells from
C. difficile toxin B-mediated damage. When taurocholate and toxin B (8 and 16 µg)
were added simultaneously to confluent Caco-2 cell monolayers, toxin-mediated
cytopathic effects were prevented (Fig. 4.1). One of the mechanisms by which C.
difficile toxins mediate cell damage is by inducing apoptosis. Specifically, toxin A
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has been reported to induce cell death in human epithelial cells ex vivo by activating
caspases (23, 29, 71). The data presented demonstrate for the first time that toxin B
increases caspase-3 activity in Caco-2 cells in a dose-dependent manner (Fig. 4.2).
Moreover, the data presented established that taurocholate reduced caspase-3
activity in the presence of lethal toxin B concentrations.
The concentration of taurocholate used in this study did not affect either the
growth or toxin production of C. difficile strains tested. However, it significantly
decreased total toxin activity in all the strains tested. It is important to note that the
lowest percent inhibition of toxin activity was observed in strains that produce high
levels of the toxins, suggesting that more taurocholate may be necessary to
neutralize the toxins.
The mechanism of taurocholate-mediated inhibition of C. difficile toxin activity
remains to be determined. Brandes et al. (20) reported that tauroursodeoxycholic
acid, a modified conjugated bile acid, affected the host cell by inducing
phosphorylation of Rac1/Cdc42 that inhibited C. difficile toxin B-mediated
monoglucosylation of this GTPase. Taurocholate may function through hydrophobic
interactions to saturate the Caco-2 cell membranes, thereby inhibiting toxin entry
and/or toxin activity. Other inhibitory mechanisms may involve direct effects of
taurocholate on toxins such as alterations to toxin structure leading to loss of
activity, or binding of taurocholate to the toxins leading to the prevention of entry
into the host cell. Further research is on-going to identify the mechanism of
taurocholate action.
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One limitation of this ex vivo study was the inability to co-culture C. difficile with the
Caco-2 cells in the presence of taurocholate; C. difficile does not grow under
aerobic conditions, and Caco-2 cells do not grow under anaerobic conditions. Thus,
an in vivo C. difficile animal model is required to provide more insight into these
findings.
It is important to note that the majority of nutrient absorption in the
gastrointestinal tract occurs in the small intestine where bile salts are at much
higher concentrations compared to the colon. This difference in bile salts
concentration is due to the reabsorption of more than 95% of the total human bile
via the enterohepatic circulation in the ileum (55), which is directly proximal to the
colon. Clearly, only a small amount of bile salts enter the colon where C. difficile
most frequently colonizes. An intriguing explanation for the CDI pathology being
mostly limited to the bile salt-deficient colon and the associated sparing of the bile
salt-rich small intestine is that toxin activity may be inhibited in the small intestine by
the high bile salt concentrations. Our data suggest that these toxins are active in the
colon because of its low bile salt concentrations. These results highlight the point
that the bile salt concentration represents a host-mediated mechanism that naturally
protects the absorptive surfaces of the small intestine from deleterious microbial
products produced by pathogens such as C. difficile and acts to inhibit bacterial
growth. Moreover, the lack of bile salts in the small intestine in disease states (such
as cirrhosis of the liver) may lead to bacterial overgrowth and result in a competition
for the essential nutrients required for normal human growth and function. The
therapeutic benefits of bile salts are well documented; they prevent hepatocyte
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injury and cholestasis (93, 94, 172), drug-induced cholestasis (174), and endotoxin
absorption (9, 80). We suggest that uncovering a mechanism to deliver higher
concentrations of bile salts and/or their derivatives, perhaps in conjunction with
antibiotics into the colon of individuals suffering from recurrent CDI may help protect
the colon from the damaging effects of the C. difficile toxins and facilitate clearance
of the pathogen. This line of research may result in a novel treatment of CDIs that
can produce recurrent and chronic disease or death.

I have demonstrated in Chapters 2-4 that a more sensitive and specific C.
difficile toxin assay that was required to perform the experiments necessary to
confirm the hypothesis set forth in this study has been successfully developed. The
next chapter describes how the new assay was utilized to provide insight into the
regulation of the C. difficile toxins.

96

CHAPTER 5: QUORUM SIGNALING-MEDIATED REGULATION OF
CLOSTRIDIUM DIFFICILE TOXIN SYNTHESIS
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INTRODUCTION

The prevalence of C. difficile infections (CDI) has been increasing exponentially
within the last decade, causing between 1-3.2 billion U.S. dollars annually in
healthcare cost (124, 226). The morbidity and mortality resulting from C. difficileassociated diseases have also increased significantly as a result of changes in the
virulence of the causative strains, antibiotic usage patterns, increases in the number
of the elderly and immune-compromised patients, and the lack of proper infection
control (143, 160, 177). Treatment of CDI is hampered by recurrence, multi-drug
resistance, and the limited number of antibiotics with functional activity in the colon.
In addition, a large number of C. difficile isolates are resistance to the majority of
antibiotics currently used in hospitals and outpatient settings (6, 16, 164, 193). As a
result of the dwindling number of antibiotics that are able to effectively clear this
infection and prevent recurrence, there is a renewed interest in exploring a nonantibiotic treatment approach to CDI.
The range of disease symptoms caused by C. difficile is variable and the
severity depends on the level of toxins produced (3). This indicates that toxin
production is a critical and significant element in C. difficile pathogenesis. Therefore,
the inhibition of toxin synthesis is a promising approach to combating CDI.
Furthermore, targeting the regulatory mechanisms that control toxin production and
other virulence factors that do not affect growth would be ideal. They are unlikely to
generate a selective pressure on the bacterium and as a result, the risk of
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developing resistance would be minimized. However, currently little is known about
the mechanisms and factors that regulate C. difficile toxin synthesis.
Bacterial cell-to-cell communication has been shown to control the pathogenesis
of a variety of bacteria by regulating virulence factor synthesis (31). Most forms of
intercellular communication involve the extracellular generation of small soluble
diffusible signals that accumulate in the environment and reach a critical threshold
when the cell density reaches a specific level. This cell density-dependent
regulation was first identified in Vibrio fisheri more than 30 years ago and is now
termed quorum signaling (67). Bacterial quorum signaling regulates processes that
require the co-operation of a population of bacterial cells in order to be effective;
individual cells in the group benefit from the activity of the entire assembly (42, 148,
188). The Gram-negative bacteria produce various types of N-acyl-homoserine
lactones that are synthesized by enzymes encoded by the luxI family of genes.
Another signaling molecule designated as autoinducer-2 (AI-2), which is
synthesized by enzymes encoded by the luxS family of genes, is involved in quorum
signaling in both Gram-negative and Gram-positive bacteria (53, 216). AI-2 appears
to mediate both intraspecies and interspecies communication in bacteria (189, 230).
AI-2/luxS-mediated regulation is important in controlling different activities in a
variety of bacterial species (230). These activities include biofilm production in
Streptococcus mutans, Salmonella enterica serovar typhimurium, and Vibrio cholera
(88, 147, 173, 232); motility in Campylobacter jejuni, enterohemorrhagic Escherichia
coli (EHEC), and enteropathogenic E. coli (62, 75, 197); and expression of virulence
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factors

in

Aggregatibacter

actinomycetemcomitans,

EHEC,

Porphyromonas

gingivalis, V. cholerae, and Clostridium perfringens (36, 66, 161, 196, 236).
Another Gram-positive-specific quorum signaling system, the accessory gene
regulator (agr) system, has been shown to regulate virulence in Staphylococcus
aureus and other Gram-positive bacteria. The agr quorum signaling system is
specific to Gram-positive bacteria. It is transcribed as an operon and consists of 5
genes: agrA, B, C, D, and RNAIII. The agrD encodes an autoinducer pre-peptide,
which is processed by the transmembrane protein AgrB, leading to release of the
autoinducer peptide (AIP) into the extracellular milieu. The AgrC (sensor histidine
kinase) protein senses the AIP, which activates its ATPase activity leading to
phosphorylation of AgrA (the response regulator). Phosphorylated AgrA either binds
to the promoter region of the agr operon to produce more of the agr system
components or the RNAIII promoter to regulate the transcription of its target genes.
The genome of C. difficile encodes both the luxS gene and agrB and agrD
genes of the agr system. However, neither of these quorum signaling systems has
been unquestionably shown to be involved in toxin synthesis regulation. In C.
difficile, toxin synthesis occurs during the stationary phase of growth, which also
corresponds to high cell density. To elucidate the processes that govern the
production of these toxins, the C. difficile stationary phase culture supernatant fluid
was analyzed for the presence of factors or molecules that induce toxin production.
This Chapter describes and discusses the results from the analyses of the
stationary phase culture supernatant fluid, which was based on the hypothesis that
the synthesis of C. difficile toxins A and B is cell density-dependent and involves a
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signaling pathway that responds to extracellular cues for regulation. The goal was to
understand the regulation of C. difficile toxins A and B synthesis, to enable the
identification of the key players involved, with the hope of discovering potential
novel genes, molecules, or pathways that could be targeted therapeutically for the
prevention and treatment of C. difficile infections.

101

MATERIALS AND METHODS

5.2.1 Bacterial Strains and Growth Conditions
Toxigenic C. difficile strains ATCC BAA-1805 (tcdA+/B+; NAP1/027), ATCC
BAA-1875 (tcdA+/B+, NAP7) and ATCC BAA-1382 (tcdA+/B+, strain 630) were
purchased from the American Type Culture Collection (ATCC, Manassas, VA). The
clinical isolates were kindly provided by Dr. Kevin Garey (University of Houston,
Houston, Texas). These isolates are: R20291 (NAP1), CD196 (NAP1), BI-9 (NAP2),
TL176 (NAP4), CF5 (NAP9), and Liv022 (NAP11). The strain BAA-1382 was used
for all the experiments, unless stated, because no regulatory mutations, such as a
tcdC deletion or a tcdC open reading frame shift have been reported in this strain.
The bacterial cultures were grown in BBL Brain Heart Infusion (BHI) medium
(Becton Dickinson and Company, Cockeysville, MD) or single colonies were
isolated on the Cdifftox agar (40) plates. Cultures were incubated anaerobically in
an atmosphere of 10% H2, 5% CO2, and 85% N2 at 37°C in a Controlled
Atmosphere Anaerobic Chamber (PLAS LABS, Lansing, MI). The BHI medium used
in all the experiments was reduced by placing it in the anaerobic chamber for at
least 4 hrs prior to use. The substrate for the Cdifftox activity assay (41), pNitrophenyl-β-D-glucopyranoside, was purchased from Biosynth International
(Itasca, IL).
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5.2.2 Sample Storage Conditions for the Bacterial Stocks
Bacterial stocks were stored short-term in chopped meat broth (BD Diagnostics,
NJ) at room temperature or long-term in either 10% dimethyl sulfoxide or 15%
glycerol stocks at -80°C.

5.2.3 Toxin Assay
C. difficile toxins A and B were detected in the culture supernatant fluid using
the Cdifftox activity assay (41), as described in Chapter 2. Briefly, the culture was
centrifuged for 15 min at 3200 x g at 4oC, 240 µl of the supernatant fluid was
incubated with 30 µl of Cdifftox substrate reagent containing 45 mM p-Nitrophenylβ-D-glucopyranoside and incubated at 37oC for 4 hrs. The assay was quantitated
spectrophotometrically at an absorbance of 410 nm. A molar extinction coefficient
for p-nitrophenol of ε = 17700 M-1cm-1 was used for the calculations (192).

5.2.4 C. difficile Quorum Signaling Bioassay
The C. difficile quorum signaling bioassay was performed by incubating lowdensity log-phase cells with culture supernatant fluid collected from stationaryphase cells. This assay was based on the premise that the presence of toxininducing activity in the stationary-phase culture supernatant should induce lowdensity log-phase cells to produce the toxins. These toxins are normally produced
during the stationary phase of the growth cycle. Thus, log-phase cells when
incubated with stationary phase supernatant fluid must behave as though they are
in stationary-phase and produce the toxins. The scheme of how this assay was
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performed is shown in Figure 5.1. Briefly, the culture supernatant fluid was collected
at various growth phases: 4 hrs (log phase), 8 hrs (late-log phase to early-stationary
phase), 16 hrs (mid-stationary phase) and 26 hrs (late-stationary phase). For the
assay, 100 µl of washed low-density log-phase tester cells (prepared as described
below) was added to a medium containing 3 ml of the stationary phase supernatant
fluid (prepared as described below) and 2 ml of fresh reduced BHI medium. The
medium was incubated for 4-8 hrs anaerobically at 37oC. As a control, the lowdensity log-phase tester cells were added to 5 ml of fresh reduced BHI medium and
incubated under the same conditions as the treated cells. At the end of the
incubation period, the culture was centrifuged at 3200 x g for 15 min and the
supernatant fluid was tested for the presence of the toxins using the Cdifftox activity
assay (41). After the boiling experiment (described in section 5.2.7), all the
subsequent experiments were performed using boiled supernatant fluid collected at
72 hrs instead of a 26-hr culture supernatant fluid.

5.2.5 Collection of Culture Supernatant Fluid for C. difficile Quorum Signaling
Bioassay
An overnight culture (O.D. 600 nm of 1.5) was generated from a single colony of
C. difficile strain 630. The culture was diluted 1:100 with fresh reduced BHI medium
and incubated anaerobically at 37oC. Aliquots of the culture were collected at 4 hrs
(log phase), 8 hrs (late-log phase to early-stationary phase), 16 hrs (mid-stationary
phase) and 26 hrs (late-stationary phase). The culture was centrifuged at 3200 x g
for 20 min and the supernatant fluid was filtered using 0.2 µm SFCA filter (Corning
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Incorporated, Corning, NY). The filtered supernatant fluid was stored at 4oC until
use.

5.2.6 Preparation of Tester C. difficile Cells for Quorum Signaling Bioassay
A single colony of C. difficile strain 630 was selected from a Cdifftox agar plate
(40) and cultured in 10 ml of fresh BHI medium overnight (14-16 hrs). The overnight
culture (O.D. 600 nm = 1.4-1.5) was centrifuged at 3200 x g for 20 min and washed
twice with fresh reduced BHI medium. The washed culture was diluted 1:100 with
fresh BHI medium and incubated for 4 hrs (mid-log phase). For the quorum
signaling experiment, 100 µl or 1:50 dilution of the tester cells was used.

5.2.7 The Effect of Boiling of the Stationary Phase Culture Supernatant Fluid
on C. difficile Toxin Synthesis
Culture supernatant fluid (45 ml) was collected from the late-stationary phase
(26 hrs) and prepared as described above. The supernatant fluid was boiled for 20
min and allowed to cool at room temperature. The boiled supernatant fluid was
centrifuged at 3200 x g for 20 min and sterilized with a 0.2 µm SFCA filter. For the
bioassay, the boiled supernatant fluid (3 ml) was diluted with 2 ml of fresh reduced
BHI medium and added to 100 µl of washed low-density log-phase tester cells. The
culture was incubated for 8 hrs anaerobically at 37oC and the supernatant fluid was
tested for toxin-inducing activity.
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Figure 5.1: The C. difficile quorum signaling bioassay. Low density C. difficile cells
at log phase (tester cells) were suspended in stationary phase culture supernatant
fluid and incubated for 4-8 hrs anaerobically at 37oC. The culture supernatant fluid
was tested for the presence of toxins using the Cdifftox activity assay.
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5.2.8 Dialysis of the Stationary Phase Culture Supernatant Fluid
Culture supernatant fluid collected after 72 hrs of incubation and boiled as
described above, was dialyzed in fresh BHI medium for 18 hrs. The culture
supernatant fluid was placed into a seamless cellulose dialysis membrane (SigmaAldrich, St. Louis, MO) with different molecular weight cut-off values (1-, 3.5-, and
12- kDa MWCO). The dialysis membranes containing the sample (15 ml) were
placed in a flask containing 500 ml of fresh BHI medium and incubated at 4oC on a
magnetic stirrer. The fluids in the dialysis membranes were tested for toxin-inducing
activity using the quorum signaling bioassay. The bioassay was performed by
adding low-density log-phase cells (100 µl) to 1 ml of the fluid in the dialysis
membranes and 4 ml of fresh reduced BHI medium. The culture was incubated for 4
hrs anaerobically at 37oC and tested for toxin-inducing activity.

5.2.9 Effect of Cell Density on Induction of C. difficile Toxin Synthesis
An artificially high cell density was created by culturing the cells in a dialysis
membrane with a 12 kDa MWCO. This experiment was set up in three flasks as
shown in Figure 5.2. Flask 1 contained 220 ml of fresh reduced BHI medium and 10
ml of low-density log-phase cells at O.D. 600 nm of 0.05. Flask 2 contained 220 ml
of fresh reduced BHI medium and a 12-kDa MWCO dialysis membrane containing
10 ml of low-density log-phase cells at O.D. 600 nm of 0.05. Flask 3 was similar to
Flask 2, but the BHI medium was removed and replaced with fresh medium after
every 4 hrs. The three flasks were incubated for 8 hrs anaerobically at 37 oC.
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Figure 5.2: Effect of cell density on induction of toxin synthesis in C. difficile. An
artificially high cell density was created by growing the cells in 12-kDa MWCO
dialysis membranes. In Flask 1, cells were cultured as normally performed using 10
ml of low-density log-phase cells. In Flasks 2 and 3, the same amount of cells as in
Flask 1 were added to dialysis membranes and placed in a flask containing fresh
reduced BHI medium. The BHI medium in Flask 3 was removed and replaced with
fresh BHI medium after 4 hrs whereas, the medium in Flask 2 remained unchanged.
Culture supernatant fluid in the dialysis membranes and Flask 1 were tested for
toxin activity using the Cdifftox assay.
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Culture supernatant fluids in the dialysis membranes (for Flasks 2 and 3) as well as
the culture in Flask 1 were tested for the toxin activity after the incubation period.

5.2.10 Effect of Known Autoinducers on C. difficile Toxin Synthesis
Autoinducers from the LuxS and agr quorum signaling systems were tested to
evaluate their effect on C. difficile toxin synthesis. For the LuxS autoinducer, 4, 5Dihydroxy-2, 3-pentanedione (DPD) was purchased from OMM Scientific (Dallas,
Texas). The predicted putative C. difficile agr autoinducer cyclic peptide
(NSTCPWII) was synthesized and kindly provided by Dr. Weng Chan and Dr. Paul
Williams (Centre for Biomolecular Sciences, University of Nottingham, U.K.).
Different concentrations of DPD (1 nM, 10 nM, 100 nM, 1µM, 10 µM, 50 µM, and
200 µM) and 10-50 µg/ml of the cyclic peptide NSTCPWII were incubated with lowdensity log-phase tester cells for 8 hrs and the culture supernatant fluid was tested
for toxin activity.

5.2.11 Multiple Sequence Alignment of the agrD Gene in Gram-Positive
Bacteria
To compare the similarities of the agrD gene sequence among Gram-positive
bacteria, the amino acid sequences of this gene from various Gram-positive
bacteria were analyzed using multiple sequence alignment. This analysis was
performed using BioEdit (Ibis, Biosciences, Carlsbad, CA). The sequences from
following bacteria were analyzed: Clostridium difficile, Clostridium botulinum,
Clostridium

sporogenes,

Eubacterium

ventriosum,

Eubacterium

rectale,
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Staphylococcus epidermidis, Staphylococcus simiae, Staphylococcus intermedius,
and Staphylococcus aureus.

5.2.12 Purification of the C. difficile Toxin-Inducing Activity From StationaryPhase Culture Supernatant Fluid
The toxin-inducing activity in the stationary-phase supernatant was purified from
boiled supernatant using the purification scheme outlined in Figure 5.3. Briefly, a
48-hr culture (500 ml) from C. difficile strain 630 was prepared as described above.
The supernatant was boiled for 20 min to inactivate the toxins. The sample was
cooled, and centrifuged for 20 min at 3200 x g to remove the denatured toxins and
other high molecular weight proteins. The clear supernatant fluid was precipitated in
60% ice-cold acetone and incubated overnight at -20oC. The precipitate was
centrifuged at 3200 x g for 10 mins and the pellet was carefully washed with milliQ
water. The washed pellet was re-suspended in 20 ml of milliQ water and incubated
at 4oC overnight. A white crystal-like precipitate was observed at the bottom of the
tube after the overnight incubation (Fig. 5.3). The top liquid portion was decanted
and the crystal-like material (CRYS) was re-dissolved in milliQ water and sterilized
with a 0.2 µm SFCA filter. To test for the presence of toxin-inducing activity in
CRYS, low-density log-phase tester cells (100 µl) were added to fresh reduced BHI
medium (5 ml) containing 200 µl of CRYS and incubated anaerobically for 4 hrs at
37oC. The culture supernatant fluid was tested for toxin activity. To evaluate
whether CRYS could induce toxin synthesis in a dose-dependent manner, different
amounts of CRYS (100, 200, 300, and 400 µl) were tested as described above.
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Figure 5.3: Scheme for the purification of C. difficile toxin-inducing activity from
stationary-phase culture supernatant fluid. Culture supernatant was boiled and
centrifuged to inactivate the toxins and to eliminate high molecular weight proteins.
The supernatant fluid was precipitated in 60% ice-cold acetone overnight. The
precipitate was washed with water, re-suspended, and incubated at 4oC overnight.
Crystal-like material that formed after the overnight incubation was re-dissolved in
water and tested for toxin-inducing activity, followed by high performance liquid
chromatography (HPLC) purification.
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5.2.13 Effect of the Partially Purified Toxin-Inducing Activity (CRYS) on
Growth of C. difficile and Transcription of the tcdA and tcdC Genes
Tester C. difficile strain 630 cells at O.D. 600 nm of 0.6 were diluted 1:100 in
fresh reduced BHI medium (35 ml) containing 2 ml of the partially purified toxininducing material (CRYS) and incubated anaerobically at 37 oC for 16 hrs. As
negative control, the tester cells were cultured in fresh BHI medium without CRYS.
Aliquots of the culture were taken every 2 hrs for a measurement of growth at O.D.
600 nm, toxin testing, and mRNA analysis.

5.2.14 Analysis of tcdA and tcdC Transcription
Total RNA was isolated using Tri-Reagent (Molecular Research Center,
Cincinnati, OH) according to the manufacturer’s directions. The mRNA was
converted to cDNA by reverse transcription using ProtoScript AMV First Strand
cDNA Synthesis kit (New England bioLabs, Ipswich, MA) according to the
manufacturer’s instructions. For reverse transcription, 1 µg of total RNA was used.
The primers used for the PCR were: tcdA: F-5-TGCCAGAAGCTCGCTCCACA3’, R5’TGCACTTGCTTGATCAAAGCTCCA3’; tcdC: F-5’GAGCACAAAGGGTATTGCTCTACTGGC3’, R-5’CCAGACACAGCTAATCTTATTTGC-ACCT3’. The PCR was
performed using OneTaq HS Quick-Load 2X master mix (New England BioLabs)
with the following conditions: initial denaturation of 94 oC for 30 sec and 36 cycles of
94oC for 30 sec, 56oC for 30 sec, and 68oC for 30 sec. The PCR products were
separated by 1.5% agarose gel electrophoresis and stained with ethidium bromide.
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5.2.15 Effect of the Partially Purified Toxin-Inducing Activity on Toxin
Synthesis in High Density Cells
To gain insight into the sensitivity of cells to the presence of the toxin-inducing
activity, tester cells at different cell densities were evaluated with the bioassay.
Tester cells were grown to O.D. 600 nm of 1.5 and washed twice with fresh reduced
BHI medium. A 100 µl (1X), 500 µl (5X) and 1000 µl (10X) of the tester cells were
added to fresh reduced BHI (5 ml) containing 200 µl of CRYS. The culture was
incubated for 90 min anaerobically at 37oC and the supernatant fluid was tested for
toxin activity.

5.2.16 Effect of the Partially Purified Toxin-Inducing Activity on Epidemic
Strains of C. difficile
The effect CRYS on toxin synthesis in clinical epidemic hypervirulent strains of
C. difficile was evaluated. The following strains were tested: ATCC BAA-1832 (nonepidemic historical strain), ATCC BAA-1805 (NAP1/027), R20291 (NAP1), CD196
(NAP1), BI-9 (NAP2), TL176 (NAP4), ATCC BAA-1875 (NAP7), CF5 (NAP9), and
Liv022 (NAP11). The standard quorum signaling bioassay was performed on these
strains, as previously described. The tester cells (100 µl) were added to fresh
reduced BHI medium (5 ml) containing 200 µl of CRYS and incubated anaerobically
for 4 hrs at 37oC. For a negative control, the tester cells were incubated in fresh
reduced BHI without CRYS. Culture supernatant fluid was tested for toxin activity at
the end of the 4-hr incubation period using the Cdifftox activity assay.
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5.2.17 Purification of the Partially Purified Toxin-Inducing Activity by High
Performance Liquid Chromatography
CRYS was further purified by high performance liquid chromatography (HPLC)
using a Shimadzu Prominence HPLC System (Shimadzu Scientific Instruments,
Columbia, MD) with a Phenomenex Jupiter 4µ Proteo 90A (250 mm x 4.6 mm) C18
column (Phenomenex, Torrance, CA). CRYS was diluted 5-fold with HPLC-grade
water and 100 µl was injected onto the column. The purification was performed with
HPLC-grade water as buffer A and acetonitrile as buffer B. A gradient of acetonitrile
from 0-95% in 15 min at a flow rate of 0.5 ml/min was used. Fractions (0.5 ml) were
collected and dried using a SPD111 speedvac (Thermo Scientific). To identify
fractions that contained the toxin-inducing activity, the dried fractions were resuspended in 200 µl of milliQ water and 100 µl was added to 3 ml of fresh reduced
BHI medium containing 50 µl of the tester C. difficile strain 630 cells. The culture
was incubated for 4 hrs anaerobically at 37oC and the supernatant fluid was tested
for toxin activity.

5.2.18 Mass Spectrometry Analysis
The fraction (Fraction #6, which eluted at 5.2 min) from the HPLC purification
that induced toxin synthesis in the tester cells was analyzed by MALDI-ToF mass
spectrometry by the Rice University Shared Equipment Facility (Rice University,
Houston, TX) and the Institute for Biomolecular Design (University of Alberta,
Canada).
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RESULTS

5.3.1 C. difficile Stationary Phase Culture Supernatant Fluid Induces Toxin
Synthesis in Low-Density Log-Phase Cells
Toxin synthesis in C. difficile occurs during the stationary-phase of growth. The
toxins were detected in the culture supernatant fluid by the Cdifftox activity assay
between 14-16 hrs during normal liquid growth. To test whether the stationaryphase culture supernatant fluid contained an activity that could induce toxin
synthesis, supernatant fluids were collected at 4 hrs (log phase), 8 hrs (late-log
phase to early-stationary phase), 16 hrs (mid-stationary phase) and 26 hrs (latestationary phase) from C. difficile strain 630 during normal liquid growth. These
supernatant fluids were added to uninduced low-density log-phase cells (tester
cells), incubated for 8 hrs and the resulting supernatant was tested for induction of
toxin activity. Under these conditions, no toxin activity was detected in the culture
supernatant fluid when the tester cells were incubated with either fresh reduced BHI
medium or 4-hr culture supernatant fluid (Fig. 5.4). In contrast, toxin activity was
detected in the culture supernatant fluid when the tester cells were incubated with
spent supernatant fluids collected from 8, 16, and 26 hrs cultures. These data
suggest that the stationary-phase culture supernatant fluid contained an activity that
induced toxin synthesis.
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Figure 5.4: The effect of C. difficile stationary-phase spent culture supernatant fluid
on toxin synthesis. Log-phase low-density cells were incubated for 8 hrs
anaerobically at 37oC with spent culture supernatant fluid collected from the
exponential phase (4 hrs), early-stationary phase (8 hrs), mid-stationary phase (16
hrs), and late-stationary phase (26 hrs). The resulting culture supernatant fluid was
tested for toxin activity using the Cdifftox activity assay.
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During bacterial growth, cell density increases with incubation after the initial lag
phase through the exponential phase and into the stationary phase. During
stationary phase, the cell density remains relatively constant. At this stage,
equilibrium is reached between the rate of cell division and the rate of cell death.
This equilibrium is eliminated when the growth medium cannot sustain the
burgeoning cell density. At late-stationary phase, the essential nutrients in the
medium become limited, metabolic products and metabolic wastes build up, cell
division slows down, and more bacterial cells die. The stationary phase in C. difficile
is unusually long, lasting approximately 30 hrs (Fig. 2.10); it is during this time that
the toxins are produced. Our data reveal that the 4-hr exponential phase culture
supernatant collected from cells at low density did not induce toxin synthesis.
Furthermore, there was an increase in the stimulation of toxin activity with spent
supernatant fluids that were from later stages of growth (Fig. 5.4). These results
imply that the culture supernatant fluid collected at late-stationary phase contained
a greater amount of the toxin-inducing activity than the supernatant fluid collected
from the early stationary phase. Moreover, the cell density at 26 hrs was higher than
the cell density at 8 hrs. These results suggest that the production of toxin-inducing
activity was cell density-dependent and accumulated during C. difficile growth.

5.3.2 Characterization of the Toxin-Inducing Activity in C. difficile StationaryPhase Culture Supernatant Fluid
To assess the nature and stability of the toxin-inducing activity, the latestationary-phase culture supernatant fluid was boiled for 20 min and tested using
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the quorum signaling bioassay for induction of toxin synthesis. Boiling the spent
culture supernatant fluid reduced the toxin-inducing activity by only 25% (Fig. 5.5A).
This result demonstrates that the majority of the toxin-inducing activity is heat
stable. As a result, all the subsequent experiments were performed using boiled
supernatant fluid collected at 72 hrs instead of a 26-hr culture supernatant fluid. The
boiling of the supernatant fluid inactivated the toxins present and thus, eliminated
the effect of “carry-over toxins” in the subsequent assays. Moreover, using a 72-hr
culture supernatant fluid reduced the incubation time required for induction of toxin
synthesis from 8 hrs to 4 hrs, because there was a greater amount of the toxininducing activity present in the 72-hr spent supernatant fluid.
To establish the putative size of the toxin-inducing activity, the culture
supernatant fluid was dialyzed with membranes of different molecular weight cut-off
sizes. This was performed by suspending the dialysis membranes containing the
supernatant fluid in fresh BHI medium overnight at 4 oC and testing for either
retention or loss of the toxin-inducing activity. Induction of toxin synthesis was lost
when the spent culture supernatant fluid was dialyzed with all of the dialysis
membranes (1, 3.5, 12 kDa MWCO). These data suggest that a small molecule that
is probably less than 1 kDa is responsible for the toxin-inducing activity.
All together, these results established that during growth C. difficile generates a
small (< 1 kDa), heat-stable, toxin-inducing factor into the extracellular milieu that
accumulates and subsequently activates toxin synthesis.

118

Figure 5.5: Toxin-inducing activity in boiled (A) and dialyzed (B) stationary-phase
spent culture supernatant fluid. A, Cdifftox Activity assay was performed on culture
supernatant collected from low-density log-phase tester cells incubated with fresh
BHI medium, boiled, and unboiled 26-hr culture supernatant fluid and incubated for
8 hrs anaerobically at 37oC. B, Cdifftox Activity assay was performed on culture
supernatant fluid collected from log-phase low-density tester cells incubated for 4
hrs anaerobically at 37oC with boiled 72-hr spent culture supernatant fluid dialyzed
with membranes of various molecular weight cut-offs (12 KDa, 3.5 KDa, 1 KDa).
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5.3.3 Artificially-Created High Cell Density Induces Premature Toxin Synthesis
in C. difficile
The stationary phase at which C. difficile produces the toxins corresponds to
high cell density. It was postulated that accumulation of the toxin-inducing activity
present in the spent stationary-phase supernatant increases with cell density. To
investigate this hypothesis, the C. difficile tester cells were cultured in a 12-kDa
MWCO dialysis membrane. The membrane was placed in a flask containing fresh
reduced BHI medium and incubated anaerobically for 8 hrs at 37oC. The culture
medium surrounding the dialysis membrane was either changed or remained
unchanged during the incubation period. Under this condition, the toxins were
retained in the dialysis membrane due to their large size (toxin A [308 kDa] and
toxin B [269 kDa]), whereas the small toxin-inducing activity diffused out of the
membrane into the surrounding BHI medium. The optical density of the cells that
were cultured in the dialysis membrane was approximately 3 times higher than cells
cultured normally in a flask. The resulting supernatant fluid in the dialysis membrane
was tested for the toxin activity. Under this condition, the tester cells that were
grown normally in a flask for 8 hrs were not induced and as expected, no toxin
activity was detected (Fig. 5.6). Toxin synthesis was induced in the tester cells that
were cultured in the 12-kDa dialysis membrane in which, the medium was not
changed. However, no toxin activity was detected by the tester cells that were
cultured in the 12-kDa dialysis membrane, in which the spent growth medium was
removed and replaced with fresh medium, despite the high cell density. Changing
the spent growth medium is expected to have removed the toxin-inducing activity
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from the medium, thus, prohibiting the induction of toxin synthesis. These results
support the idea that toxin synthesis in C. difficile is cell density-dependent and
involves accumulation of an inducing factor, which increases with cell density.

5.3.4 The LuxS and Agr quorum Signaling Systems do not Influence Toxin
Synthesis in C. difficile
The genome of C. difficile encodes two known quorum signaling systems; the
LuxS and the accessory gene regulator (agr) systems. The signaling molecule
utilized by the LuxS quorum system (AI-2) is a by-product of the activated methyl
cycle, which recycles S-adenosyl-L-methionine (SAM). SAM is the main methyl
donor in archaea, prokaryotes, and eukaryotes that supplies methyl groups to
biomolecules such as DNA and proteins. In the activated methyl cycle, SAM is
converted to S-adenosyl-L-homocysteine (SAH), which is toxic to cells. In
eukaryotes, SAH is converted to non-toxic homocysteine in a single step (228).
However, in archaea and prokaryotes, SAH is detoxified in a two-step process, first
by the Pfs enzyme (S-adenosylhomocysteine nucleosidase) to generate adenine
and S-ribosylhomocysteine (SRH). SRH is finally converted by LuxS (Sribosylhomocysteinase)

to

4,5-dihydroxy-2,3-pentanedione

(DPD)

and

homocysteine (188, 228). DPD undergoes spontaneous cyclization and it can be
sensed and modified by different bacterial species as a signaling molecule that
controls gene expression.
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Figure 5.6: Early induction of toxin production under artificially high cell density
conditions. Cells were cultured in 12-kDa MWCO dialysis membranes and placed in
a flask containing fresh BHI medium. The spent BHI medium was either changed at
4 hrs or remained unchanged during an 8-hr incubation period and samples were
taken from the dialysis membranes for toxin assay using the Cdifftox activity assay.

122

To investigate whether the LuxS autoinducer influences toxin production in C.
difficile, different concentrations of the precursor DPD were provided exogenously
to the log-phase tester cells and incubated for 8 hrs. DPD did not activate toxin
synthesis (Fig. 5.7), suggesting that the LuxS system is not involved in the
regulation of C. difficile toxin production. This result is consistent with the work
reported by Carter et al. (31), which also found no association between C. difficile
toxin production and the LuxS system.
Analysis of the genome of C. difficile revealed the presence of agrB and agrD,
but putative homologues of agrC and agrD were not identified either around the
vicinity of the agr locus or elsewhere in the genome. However, the genome does
encode at least 37 two-component signal transduction systems. It is unusual to find
agrB and agrD homologues without agrA and agrC homologues, because the agr
components form an operon in other Gram-positives such as Staphylococcus
aureus and are normally transcribed together. Multiple sequence alignment of the
agrD locus from sequenced C. difficile strains showed that agrD is highly conserved
in C. difficile (Fig. 5.8A), unlike the agrD in S. aureus, which is less conserved. In
fact, four different autoinducer peptides (AIPs) have been identified in S. aureus that
each control different effector targets. From the multiple sequence alignment, a
cysteine (Cys-28) was found to be conserved in all of the different agrD sequences
analyzed. In S. aureus, the AIPs contain a thioester bond between Cys-28 and the
fourth amino acid towrds the C-terminus.
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Figure 5.7: LuxS quorum signaling molecule (AI-2) does not influence toxin
production in C. difficile. Log-phase C. difficile strain 630 tester cells were incubated
for 8 hrs anaerobically at 37oC with different concentrations of 4,5-dihydroxy-2,3pentanedione. The culture supernatant fluid was tested for toxins using the Cdifftox
activity assay.
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Figure 5.8: Analysis of the agrD locus in a subset of the Gram-positive bacteria. A.
Multiple sequence alignment of the AgrD amino acid sequences from different
Gram-positive bacteria. B. Putative C. difficile AIP showing the expected thioester
bond between Cys-28 and isoleucine (Ile-32) at the fourth position toward the Cterminus.
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Based on this observation, a predicted C. difficile AIP (Fig 5.8B) was synthesized
and evaluated for its effect on toxin synthesis. The synthesized predicted C. difficile
AIP did not influence toxin synthesis regardless of the concentration assayed (10
and 50 µg/ml) (Fig. 5.9). These results demonstrate that the predicted C. difficile
AIP synthesized was not involved in the regulation of toxin synthesis in C. difficile.
However, it would be best to test mutants in the agr system to conclusively judge
the involvement of the agr system in C. difficile toxin synthesis.

5.3.5 Purification of the Toxin-Inducing Activity from Stationary-Phase Culture
Supernatant Fluid
Having tested all the autoinducers associated with the known quorum signaling
systems in C. difficile and found no association with toxin production, the toxininducing activity was purified from the stationary-phase culture supernatant. Based
on the initial finding that the inducing activity is heat-stable, the culture supernatant
fluid was first boiled to denature all high molecular weight proteins including the
toxins and centrifuged to eliminate the debris. Next, the supernatant fluid was
precipitated in 60% acetone. A crystal-like material (CRYS) appeared at the bottom
of the tube when the acetone precipitate was washed, resuspended in water, and
incubated overnight at 4oC (Fig. 5.10, insert). CRYS induced toxin production when
incubated for 4 hrs with the tester cells.
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Figure 5.9: Effect of synthesized putative C. difficile agr autoinducer peptide (AIP)
on toxin synthesis. Two isomers eluted (A and B) during the purification of the
synthesized AIP, which were both collected and tested. C. difficile low-density logphase tester cells were incubated in fresh reduced BHI medium containing the
indicated amount of the synthesized peptides and incubated for 8 hrs anaerobically.
The toxins were tested using the Cdifftox activity assay. BHI= Brain heart infusion
medium, A10, A50 = 10, 50 µg/ml of isomer A, respectively; B10, B50 = 10, 50
µg/ml of isomer B, respectively. C200 = 200 µl of partially purified toxin-inducing
activity from C. difficile culture supernatant. The structure of the predictive C. difficile
AIP is shown in the insert.
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CRYS induced toxin production in a dose-dependent manner when different
amounts (100, 200, 300, and 400 µl) were tested (Fig 5.10). These results indicated
that the toxin-inducing activity present in the stationary-phase spent culture
supernatant fluid was precipitated and concentrated by the purification method.

5.3.6 Partially Purified Toxin-Inducing Activity (CRYS) Does not Affect Growth
but Induced Early Toxin Synthesis
To assess whether the presence of CRYS affects C. difficile cell growth, tester
cells were monitored for growth in the presence and absence of CRYS for 16 hrs.
Aliquots of the culture were taken every 2 hrs for optical density determination and
toxin testing. The data showed that CRYS did not affect the growth of the tester
cells (Fig. 5.11). The growth kinetics of tester cells cultured in the presence of
CRYS was not significantly different from cells cultured without CRYS. Furthermore,
toxin activity was detected between 2 to 4 hrs in tester cells cultured in the presence
of CRYS compared to 14 to 16 hrs for tester cells cultured without CRYS. These
data revealed that only a small amount of CRYS is required to induce toxin
synthesis. The amount of the toxins produced increased with incubation period.
These results demonstrate that the toxin-inducing activity present in the spent
stationary-phase culture supernatant fluid had been isolated, partially purified, and
concentrated.
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Figure 5.10: Effect of the partially purified inducing activity on C. difficile toxin
synthesis. Different amounts of the partially purified toxin-inducing activity were
added to tester C. difficile strain 630 cells and incubated anaerobically for 4 hrs at
37oC. The resulting supernatant fluid was tested for toxin activity using the Cdifftox
activity assay. The insert is a picture of the crystal-like material at the bottom of the
tube.
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5.3.7 Partially Purified Toxin-Inducing Activity Stimulates Transcription of the
Toxin Genes
The effect of the toxin-inducing activity on transcription of tcdA and tcdC was
evaluated. The tester cells were cultured with and without CRYS for 8 hrs. Aliquots
of the culture were collected every 2 hrs for total RNA isolation, and subsequent
cDNA synthesis by reverse transcription. PCR was performed using primers specific
for tcdA and the gene encoding tcdC. In tester cells grown in the absence of CRYS,
no mRNA transcript of toxin A was observed until after 8 hrs of growth (Fig. 5.12A).
In the presence of CRYS, tcdA mRNA was detected within 2 hrs of incubation. No
significant difference was detected in the mRNA transcripts of tcdC between cells
cultured with and without CRYS (Fig. 5.12B). However, a gradual decrease in the
tcdC mRNA transcripts was apparent in both CRYS-treated and untreated cells
from 2-8 hrs. By eight hrs of incubation, the level of tcdC mRNA transcripts had
decreased to an almost undetectable level. The mRNA level corresponding to tcdC
has been shown to be inversely proportional to that of the toxins genes (30, 39, 103,
139, 142, 143, 222). However, this inverse relationship between tcdC and tcdA
transcripts was not observed in CRYS-treated cells, suggesting that the induction of
toxin synthesis by CRYS is independent of TcdC.

130

Figure 5.11: C. difficile growth and toxin production in the presence of the partially
purified toxin-inducing activity. Tester cells (100 µl) were added to fresh reduced
BHI medium (35 ml) containing 2 ml of the partially purified toxin-inducing activity
(CRYS) and incubated anaerobically for 4 hrs at 37oC. The resulting culture
supernatant fluid was tested for toxin activity using the Cdifftox activity assay.
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Figure 5.12: Toxin-inducing activity stimulates premature transcription of tcdA.
Tester cells were cultured in the presence and absent of CRYS and aliquots were
collected every 2 hrs for total RNA isolation, followed by cDNA synthesis by reverse
transcription. PCR was performed using primers specific for tcdA (A) and tcdC (B).
‘M’ represents 1 Kb marker (New England BioLabs, Ipswich, MA); (-) = tcdA and
tcdC amplicons from cDNA synthesized from cells incubated without CRYS; (+) =
tcdA and tcdC amplicons from cDNA synthesized from cells treated with CRYS. The
PCR products were electrophoresed through a 1% agarose gel and the DNA was
detected digitally upon exposure of the ethidium bromide-treated gel to UV light.
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5.3.8 Partially Purified Toxin-Inducing Activity Stimulates Toxin Synthesis in
a Cell Density-Dependent Manner
The effect of the toxin-inducing activity on toxin synthesis in high-density cells
was evaluated to gain insight into the sensitivity of cells to the presence of the toxininducing activity. Tester cells at different densities were incubated with CRYS and
toxin synthesis was assessed after 90 min of incubation. The toxins were not
induced during the 90-min incubation period when the tester cells at different cell
densities were incubated in fresh reduced BHI medium without CRYS (Fig. 5.13). In
the presence of CRYS, toxin synthesis occurred during the 90-min incubation period
in a cell density-dependent manner. These data indicate that the transcription of the
toxin genes commenced shortly after the inducing activity was added.
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Figure 5.13: Effect of the partially purified toxin-inducing activity at different cell
densities. Tester cells were grown to an O.D. 600 nm of 1.5 and washed twice with
fresh reduced BHI medium. Different amounts of the tester cells (100 µl [1X], 500 µl
[5X] and 1000 µl [10X]) were added to fresh reduced BHI (5 ml) containing 200 µl of
CRYS. The cultures were incubated for 90 min anaerobically at 37oC and the
supernatant fluids were tested for toxin activity. Toxin detection was performed
using the Cdifftox activity assay.
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5.3.9 Partially Purified Toxin-Inducing Activity Stimulates more Toxin
Synthesis in Epidemic Hypervirulent Strains of C. difficile
Some strains of C. difficile such as the NAP1/027 strains produce high levels of
the toxins and this has been proposed to be due to a deletion or frame-shift
mutation in the tcdC gene, which allows for unregulated transcription of tcdA and
tcdB. CRYS was tested on clinical hypervirulent epidemic and non-epidemic strains
to assess its effects on toxin synthesis in these strains. Low-density log-phase cells
of the following strains: ATCC BAA-1382 (630 strain), ATCC BAA-1805 (NAP1/027
epidemic strain), R20291 (NAP1 epidemic strain), CD196 (NAP1), BI-9 (NAP2),
TL176 (NAP4), BAA-1875 (NAP7), CF5 (NAP9), and Liv022 (NAP11) were
incubated with and without CRYS anaerobically for 4 hrs and their supernatants
were tested for the presence of toxin with the Cdifftox Activity assay. In the absence
of CRYS, high basal level of toxin activity was detected in the NAP1 epidemic
strains compared to the non-epidemic strains (Fig. 5.14). A significant difference (p
= 0.004) was found between the amount of toxin activity produced by the strains
with normal wild-type tcdC [BI-9 (NAP2), TL176 (NAP4), BAA-1875 (NAP7), CF5
(NAP9), and Liv022 (NAP11)] and the strains with mutant tcdC (epidemic NAP1
strains) in the absence of CRYS. All the strains produced elevated levels of the
toxins when incubated with CRYS with no significant difference (p = 0.318) in the
amount toxins produced between the strains. These results indicate that the
inducing activity stimulated toxin synthesis via a common pathway present in all the
toxin-producing strains tested. Furthermore, this induction of toxin synthesis
appears to be independent of TcdC-mediated regulation.
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Figure 5.14: Effect of the partially purified toxin-inducing activity on epidemic
hypervirulent and non-epidemic strains of C. difficile. Log phase tester cells were
incubated with and without CRYS for 4 hrs at 37oC anaerobically. The presence of
toxins was tested using the Cdifftox activity assay. CRYS= Partially purified toxininducing activity; BHI= Reduced brain heart infusion medium; 630 = C. difficile
historical

strain

ATCC

BAA-1382

(non-epidemic

historical

strain),

1805=

Hypervirulent strain ATCC BAA-1805 (NAP1/027), 1875= ATCC BAA-1875 (NAP7),
R20291 (NAP1), CD196 (NAP1), BI-9 (NAP2), TL176 (NAP4), BAA-1875 (NAP7),
CF5 (NAP9), and Liv022 (NAP11).
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5.3.10 HPLC-Based Purification and Mass Spectrometry Analysis of the ToxinInducing Activity
The partially purified toxin-inducing activity, which was acetone-precipitated and
concentrated from the spent stationary-phase culture supernatant fluid, was further
purified by HPLC. The purification was performed in water with a gradient of
acetonitrile (0-95%). The chromatogram shows a total of 8 major peaks (Fig.
5.15A). Real-time monitoring of the purification process showed several minor
peaks that disappeared after the chromatogram was normalized. A total of 29
fractions (500 µl each) were collected and tested for induction of toxin synthesis.
Only fraction 6 was determined to contain the toxin-inducing activity (Fig. 5.15B).
The total activity obtained from fraction 6 was approximately equal to the total
activity of the partially purified sample injected onto the HPLC column. This
demonstrated that the entire toxin inducing activity, which was applied to the
column, had been collected in a single fraction. However, fraction 6 eluted very
close to the void volume at 6 min, indicating that the toxin-inducing activity
interacted weakly with the C-18 HPLC column used. Fraction 6 was sent for mass
spectrometry analysis and the results showed that there are other small
contaminants co-eluting with the toxin-inducing activity (Fig. 5.16A). Based on
MALDI-ToF mass spectrometry analysis, the molecular weight of the major
compound present in fraction 6 was 655.8 Da. This molecular weight was found to
be consistent with a cyclic compound containing a thioester linkage (Fig. 5.16B).
Further confirmatory analysis is pending, which will be followed by synthesis of this
cyclic compound to confirm its toxin-inducing activity.
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Figure 5.15: HPLC analysis of the toxin-inducing activity. A. Chromatogram from
the HPLC purification showing the normalized peaks. CRYS (100 µl) was injected
onto a Phenomenex Jupiter 4µ Proteo 90A (250 mm x 4.6 mm) C18 column
(Phenomenex, Torrance, CA). The purification was performed with water as buffer
A and acetonitrile as buffer B. A gradient of acetonitrile from 0-95% over 15 min at a
flow rate of 0.5 ml/min was used. Fractions (0.5 ml) were collected and dried using
a SPD111 speedvac (Thermo Scientific). Each fraction was resuspended in 200 µl
of water and tested for toxin-inducing activity using the quorum signaling bioassay.
B. Cdifftox activity assay showing the toxin-inducing activities of the fractions
collected. Only fraction #6 was active.
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Figure 5.16: Mass spectrometry analysis of the toxin-inducing activity (fraction # 6).
A. MALDI-ToF analysis showing the molecular weights of different compounds
present in fraction #6. B. Predicted structure of the major compound in fraction #6
based on MS/MS spectrometry analysis.
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DISCUSSION

The incidence of C. difficile infection (CDI) has been increasing at an alarming
rate to the extent that it is now the leading definable cause of nosocomial and
antibiotic-associated diarrhea (13). The major factors that have contributed to this
prevalence are the increasing use of intestinal flora-altering antibiotics, the
propensity of C. difficile to produce spores, which are refractory to disinfectants and
antibiotics, sub-optimal infection control practices, and the appearance of high toxinproducing mutant strains with a more potent activity (128, 132, 143, 153). Efficient
treatment of CDI has been mired by recurrent infections, multi-drug resistance,
difficulties in delivering appropriate drug concentrations to the colon, and the lack of
drugs with potent functional activity in the colon. As a consequence, there is
renewed interest in finding alternative treatments for CDI, either as stand-alone
therapies or therapies designed to improve the efficacy of currently used antibiotic
regimens. A promising treatment approach is to block the synthesis or activity of
toxins A and B, which are directly responsible for the CDI-associated diseases. This
line of attack, which targets the toxins without affecting cell growth, may be ideal
since it is unlikely to impose selective pressure on C. difficile, thereby minimizing
the risk of developing resistance. However, finding an appropriate specific target to
block toxin synthesis requires understanding the key players and the mechanisms
that are involved.
Under normal growth conditions, C. difficile toxin production occurs during
stationary phase. This study demonstrates for the first time that a small (< 1 kDa),
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heat-stable, cell density-dependent factor is released into the extracellular milieu by
C. difficile during growth, and activates toxin synthesis. Late-stationary-phase
culture supernatant fluid, when incubated with low-density log-phase cells, induced
higher toxin synthesis than early-stationary phase culture supernatant fluid. In
contrast, culture supernatant fluid collected from the exponential phase of growth
did not activate toxin synthesis. These results suggest that the toxin-inducing
activity accumulates during growth and peaks at stationary phase leading to
activation of toxin synthesis. This is consistent with the transcription of the toxin
genes, which begins during early stationary phase (103, 119). The hallmark of
quorum signaling is the extracellular accumulation of a small, diffusible, heat-stable,
cell density-dependent signaling molecule that induces gene expression upon
reaching a critical threshold concentration. The data presented here fulfill these
criteria and therefore, directly establishes that C. difficile toxin synthesis is regulated
by quorum signaling.
The standard signaling molecules associated with the two well-studied quorum
signaling systems (AI-2 and AIP) were tested by direct addition of the purified
molecules or their precursors in the quorum system bioassay. However, no toxin
synthesis was observed. Lee, et al. reported that cell-free supernatants from midlog phase of C. difficile and E. coli DH5α expressing recombinant C. difficile
LuxS/AI-2 increased the transcript levels of tcdA, tcdB, and tcdE (130). However,
Carter, et al. found no significant effect of LuxS/AI-2 on either the timing of toxin
production or the amount of toxins produced by C. difficile (31). The results
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presented here support the conclusion of Carter, et al. that the LuxS system is not
involved in C. difficile toxin synthesis.
The role of the agr quorum signaling system in C. difficile has not been
investigated previously. The putative autoinducer peptide derived from the C.
difficile agrD component of the agr system suggested a complex peptide containing
a linear tail and a cyclic head consisting of a thioester linkage of cysteine with
isoleucine. This unusual peptide was difficult to synthesize due to its complex
structure (Personal communication with Dr. W. Chan). Mass spectrometry analysis
confirmed the structure and actual mass of the synthesized predicted peptide to be
accurate. However, the exact nature, structure, and characteristics of the native C.
difficile AIP are not known. The C. difficile AIP was predicted based on the structure
of S. aureus AIP. Thus, the association of the agr system with C. difficile toxin
synthesis cannot be ruled out, based on the data presented in this study. It is
interesting to note that the agrD amino acid sequence is 100% conserved in all the
C. difficile strains whose genomes have been sequenced (Fig. 5.8). This suggests
that the agr AIP may be utilized by C. difficile to regulate a common process present
in all of these strains. Identification of the toxin-inducing factor or generation of C.
difficile agrD or agrB mutants may help clarify the role of the agr system in C.
difficile toxin synthesis.
The toxin-inducing activity was precipitated and concentrated from the culture
supernatant fluid. It was further purified by HPLC after confirming its activity using
the quorum signaling bioassay. By HPLC analysis, the toxin-inducing activity was
isolated in a single fraction, which was analyzed by mass spectrometry for structure
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and actual mass determination. The results from mass spectrometry indicated that
there are other compounds in the HPLC fraction that co-eluted with the toxininducing activity. It is important to note that the active fraction eluted from the HPLC
column was very close to the void volume, suggesting a weak interaction with the
C-18 column. Small molecules have traditionally been purified using C-18 columns.
Hence, the lack of strong interaction of the toxin-inducing activity with the C-18
HPLC column suggested an unusual hydrophilic small molecule. The molecular
weight of the major compound in the toxin-inducing fraction was consistent with a
655.8 Da cyclic compound. Further confirmatory analysis of this cyclic compound is
pending, which will be followed by synthesis of the compound to confirm its role in
toxin induction.
The toxin-inducing activity induced elevated levels of the toxins in different nonepidemic and epidemic strains of C. difficile, including the hypervirulent tcdC mutant
strains that naturally overexpress the toxins. The TcdC protein reportedly binds to
the TcdR transcription factor to prevent transcription of the toxin genes (30, 39, 103,
139, 142, 143, 222). Thus, a deletion or mutation in the tcdC gene would eliminate
its inhibition leading to a loss of regulation and constitutive expression of tcdA and
tcdB, which encode the toxins. Induction of elevated toxin synthesis in strains with
intact tcdC and strains with defective tcdC imply that the level of control by the
toxin-inducing activity is independent of TcdC-mediated regulation. The finding that
another factor is involved in C. difficile toxin synthesis is novel, since TcdR and
TcdC have traditionally been accepted as the only key players in C. difficile toxin
regulation.
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Based on these results, I propose that C. difficile cells produce and release a
small (<1 kDa), diffusible, heat-stable factor into their extracellular milieu that
accumulates during growth as the cell density increases (Fig. 5.16). This factor is
sensed by C. difficile cells as a measure of the population cell number. When the
factor reaches a certain critical threshold concentration, which directly reflects the
number of cells in a population, it activates a common pathway leading to a
coordinated activation of transcription of the toxin-encoding genes.
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Figure 5.17: A model for the regulation of C. difficile toxin synthesis. A signaling
factor is released extracellularly during C. difficile growth via a signal-generation
pathway that accumulates in the extracellular milieu. This signaling factor is sensed
and processed by a signaling-response pathway, thereby activating a transcription
factor that leads to the transcription of the toxins genes.
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CHAPTER 6: PERSPECTIVES AND FUTURE DIRECTIONS
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The alarming emergence and increasing incidence of C. difficile infections (CDI)
pose a public health threat and a burden to healthcare systems worldwide. The
estimated number of cases of CDI occurring in U.S. hospitals exceeds 250,000 per
year (226), with a total additional healthcare cost between 1-3.2 billion U.S. dollars
annually (124). The number of CDI cases occurring in the community and in nursing
homes, long term care facilities and skilled nursing facilities may increase the
number of annual cases in the U.S. to as many as 3 million. Morbidity and mortality
resulting from C. difficile-associated diseases in recent years have also increased
significantly. This is mainly a result of changes in the virulence of the causative
strains, antibiotic usage patterns, an aging population that includes more
immunocompromised patients, and lack of proper infection control strategies (143,
160, 177). The C. difficile toxins A and B are directly responsible for disease and
are essential in pathogenesis (73, 123, 138, 185, 219). Strains that do not produce
either of these toxins are not associated with disease. Treatment of CDI has been
hampered by recurrence, multi-drug resistance, and a lack of drugs with reasonable
bioavailability and activity in the colon. Moreover, a large number of C. difficile
isolates are resistant to the majority of antibiotics currently used in hospitals and
outpatient settings (6, 16, 164, 193). Bacterial infections have long been treated
with antibiotics, but for CDI the repertoire of available antibiotics to effectively clear
the infection and prevent recurrence is dwindling. As a result, an alternative nonantibiotic treatment approach to CDI is necessary.
The myriad of disease symptoms in CDI is variable and the severity of disease
depends on the amount of toxins produced by the infecting strain (3). This indicates
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that toxin synthesis is a critical and significant element in CDI. Therefore, an
important approach to combat CDI is inhibition of toxin synthesis and /or toxin
activity. Targeting the regulatory mechanisms that control the synthesis of these
toxins or inhibition of toxin activity are unlikely to pose a selective pressure on the
bacterium, thus minimizes the risk of resistance development compared to
antibiotics. In order to find an appropriate and specific target to effectively disrupt C.
difficile toxin synthesis, it is necessary to understand the mechanism and the key
players that are involved. Furthermore, finding an effective inhibitor of toxin activity
requires a quantitative toxin-specific assay that directly detects the activities of the
toxins. In addition, early detection of the bacterium during infection is critical to
prevent further damage by these toxins. Thus, an assay that combines detection of
the C. difficile bacterium with toxin activity would shorten the diagnosis of CDI for
early treatment intervention.
In Chapters 2 and 3, I described two related C. difficile toxin assays (the Cdifftox
activity and Cdifftox agar plate assays) developed as part of this project. The
Cdifftox activity assay enables the detection of active toxins in culture supernatant
fluid, whereas the Cdifftox agar plate assay (CDPA) detects active toxin-producing
C. difficile colonies on an agar plate. This agar plate assay allows colonies of the
infecting bacteria to be selected for further testing such as antibiotic susceptibility
testing, which is routinely done in clinical microbiology laboratories. Recently, there
has been a major shift away from the use of traditional C. difficile diagnostic
methods such as culture, ELISA, and tissue culture cytotoxicity assay to real-time
PCR-based detection of the toxin genes from stool. PCR-based methods are quick
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and sensitive, but they are based on the assumption that detection of the DNA that
encode the toxins is indicative of the presence of actively growing toxin-producing
C. difficile cells capable of causing disease. I have provided data in Chapter 3
showing that it is not unusual to detect a non-toxin-producing strain bearing the
toxin genes. There are a number of possible reasons for lack of toxin synthesis; the
strain may contain a mutation in the regulatory region or a region that encodes a
critical feature of the toxins, thereby either blocking toxin synthesis or causing the
production of inactive toxins, both of which would render a toxin gene-positive strain
clinically irrelevant. Hence, detection of the C. difficile toxin genes in stools does not
automatically translate to active C. difficile infection capable of causing disease. An
unproven concern but likely limitation of PCR-based diagnostics is that patients with
a non-CDI cause of diarrhea may be colonized by C. difficile and cause a positive
test for the toxin genes leading to an improper diagnosis. The use of PCR in CDI
diagnosis may lead to treatment for a perceived infection that is clinically irrelevant.
Overuse of antibiotics also drives resistance, which is a major problem with C.
difficile. Therefore, a diagnostic method that combines the detection of the
bacterium with active toxin production such as the CDPA, offers a better approach
to CDI diagnosis. A major limitation of CDPA is that it depends on production of the
toxins to differentiate toxin-producing strains from non-toxin producing strains.
These toxins are regulated and so a growth condition that is not conducive for toxin
synthesis may result in a false negative diagnosis. Identification of the inducing
activity discovered in this study that activates C. difficile toxin synthesis may help
eliminate this problem. I plan to modify the published CDPA assay by incorporating
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this inducing factor into the CDPA medium to activate toxin synthesis when colonies
begin to grow on the plate. This should improve the sensitivity and eliminate the
potential problem of false negative results. It is also anticipated that it will allow the
assay to detect toxin-producing strains within 24 hrs, which would be useful for
diagnosis.
The Cdifftox activity assay was used to screen for a number of compounds that
could inhibit toxin activity. Taurocholate (a common component of human bile) was
found to inhibit both toxins A and B activity. In Chapter 4, I provided data
demonstrating that taurocholate protected human colonic intestinal epithelial cells
(Caco-2 cells) from the damaging effects of the toxins. One of the downstream
effects of the toxins when internalized into the host cell cytoplasm is apoptosis. This
has been demonstrated using only toxin A (23, 29, 71). Caspase-3 is a proapoptotic protease, which commits cells to apoptosis. Using a caspase-3 assay, I
have shown for the first time that toxin B induces apoptosis in Caco-2 cells and that
taurocholate decreased the extent of toxin B-mediated apoptosis. All these
experiments were performed either in vitro or ex vivo. I plan to repeat these
experiments in a C. difficile animal model to investigate whether taurocholate could
also protect a C. difficile-infected animal model. The therapeutic benefits of bile
salts are well documented; they prevent hepatocyte injury and cholestasis (93, 94,
172), drug-induced cholestasis (174), and endotoxin absorption (9, 80). Therefore,
developing a method to deliver high or sustained concentrations of bile salts and/or
their derivatives, perhaps in conjunction with antibiotics into the colon of individuals
suffering from recurrent CDI may help protect the colon from the damaging effects
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of the C. difficile toxins and facilitate clearance of the pathogen. I also plan to take
advantage of the Cdifftox activity assay to conduct a high throughput screening of a
number of small molecule drug libraries in search of other potent inhibitors of toxin
activity, toxin synthesis, or C. difficile growth. This may lead to the discovery of
more potent drugs that could be effectively harnessed to treat CDI.
The development of the toxin assays enabled me to conduct the experiments
necessary to prove the hypothesis of this dissertation. I have demonstrated for the
first time that a small (< 1 kDa), heat-stable factor is released by C. difficile into the
extracellular milieu during growth, which peaks at high cell density. When incubated
with low-density log-phase C. difficile cells, this factor activated early and elevated
toxin synthesis. These results demonstrated for the first time that toxin synthesis in
C. difficile is regulated by quorum signaling. The predicted signals based on the two
known quorum signaling systems present in the genome of C. difficile were tested,
but did not appear to be involved in toxin synthesis. However, mutants deficient in
these systems are necessary to completely eliminate the involvement of these
systems in C. difficile toxin synthesis.
A

purification

method

was developed

that

enabled

precipitation

and

concentration of the toxin-inducing factor from stationary phase culture supernatant
fluid. This partially purified toxin-inducing factor was very potent at inducing toxin
synthesis. Analysis of tcdA and tcdC mRNA transcripts in the presence of this
partially purified toxin-inducing factor revealed an early induction of transcription of
the tcdA gene. It is widely accepted that the transcription of tcdC is inversely
proportional to the transcription of the toxin genes, suggesting a negative regulatory
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role of TcdC protein. However, this inverse relationship was not observed in the
presence of the toxin-inducing factor, suggesting that the quorum signaling
mechanism is independent of TcdC-mediated regulation. This finding was confirmed
when the toxin-inducing factor was determined to be able to induce toxin activity in
different non-epidemic and epidemic strains of C. difficile with non-functional TcdC
due to a deletion or mutation in the tcdC gene. Elevated levels of the toxins were
produced in the presence of the toxin-inducing factor by all the strains, independent
of a functional or defective TcdC. Without the toxin-inducing factor, the differences
in the amount of toxins produced by these strains were significant between the
normal strains and the tcdC mutant strains. However, no significant differences
were observed in the toxin amounts produced when the tested strains were
incubated with the toxin-inducing factor, supporting the idea that the toxin-inducing
activity is acting independent of TcdC. This finding is interesting because it is the
first evidence that other factors are involved in the regulation of toxin synthesis in C.
difficile and that TcdR and TcdC are not the only key players in toxin regulation.
With the goal of identifying the molecule responsible for the toxin-inducing
activity, I further purified the activity using HPLC. I was able to isolate the inducing
activity in a single peak. However, mass spectrometry analysis of this peak showed
that there are other molecules co-eluting with the activity. The molecular weight of
the major compound in the active HPLC fraction was a 655.8 Da, which was
consistent with a cyclic compound shown in Figure 5.16. I plan to repeat the
purification to confirm the presence of the cyclic compound as the major component
of the fraction. This will be followed by testing the activity of the synthetic compound
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to confirm its role in toxin induction. The following are some of the many questions
that would be addressed once the toxin-inducing factor is identified:
1.

Identification of the key genes and proteins involved in the generation of
the toxin-inducing activity (signal).

2.

Identification of the key genes and proteins that sense and transduce
the signal.

3.

The mechanism that governs the release, sensing, and transduction of
the signal.

4.

The connection between the signal and the pathogenicity locus, which
ultimately lead to the transcription of the toxin genes.

5.

Evaluation of the amount of the signal produced by different strains of
C. difficile.

6.

The role of the signal in the pathogenesis of C. difficile.

7.

Identify key therapeutic targets to inhibit toxin synthesis.

8.

Other target genes regulated by the signal.

The role of the toxins in the natural history of C. difficile and why they are
produced are not known. However, the syntheses of these toxins are triggered by
an event that occurs at high cell density during the stationary phase. Thus, the
benefit of these toxins to C. difficile may be related to stationary phase-associated
events such as digestion of complex biomolecules to generate readily available
nutrients to sustain the high cell density during stationary phase, detoxification of
harmful metabolites, and competition with other gut microflora for survival
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advantage. Nutrients may become limited at high cell density. These toxins are
hydrolytic with enterotoxic and/or cytopathic properties. In the mammalian host, it is
possible that these toxins are released to proteolyze tissues, thereby releasing
readily metabolisable nutrients to sustain the burgeoning cell density. CodY, is a
highly conserved pleiotropic transcription factor in low G+C bacteria that control
genes involved in adjustment to poor growth conditions (194). Dineen, et al.
reported that CodY repressed the toxin genes expression in C. difficile (51),
suggesting a link between nutrient limitation and the expression of the C. difficile
toxin genes. However, in this study nutrient limitation was not a condition that
preceded and precipitated the activation of toxin synthesis. This is because the
experiments in this study were conducted under conditions of abundant nutrients in
the medium. Thus, nutrient limitation was neither a factor nor a co-factor in the
activation of toxin synthesis. It is possible that these toxins may be produced to
release nutrients in anticipation of an impending nutrient limitation and starvation
associated with high cell density. Alternatively, it can be speculated that these
toxins are produced to release nutrients to ensure adequate nutrient supply at high
cell density. The toxins may also be produced to detoxify harmful metabolic wastes
that may build up during anaerobic growth or harmful molecules produced by other
gut flora. The effect of the toxins on other gut microflora has not been studied and it
is possible that these toxins may have a deleterious effect on other gut flora. In the
highly competitive environment of the colon, release of a molecule that could
potentially harm or impede the successful colonization of the competitor may be
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advantageous. I plan to pursue this line of research to provide more insight into the
natural history of C. difficile and how it affects the dynamics of the gut microflora.
Based on all the possible reasons presented above regarding why C. difficile
produces the toxins, it is plausible to think that the syntheses of these toxins must
be coordinated by the bacterial population producing it. This ensures that the
beneficial effects of producing the toxins are maximized. For instance, if the toxins
are produced to harm other competing bacteria, a coordinated process that enables
a large population of C. difficile cells producing the toxins at the same time would be
more effective. This is because a large amount of the toxins will be made available
to successfully eliminate the competing bacteria. This concept is supported by the
data from this study demonstrating that the C. difficile toxin synthesis is mediated by
quorum signaling. Furthermore, it appears obvious from the natural history of C.
difficile that when antibiotic therapy wipes out the normal gut flora, the overgrowth of
C. difficile may lead to rapid accumulation of the quorum signal in the colon and
induce toxin synthesis. In the presence of the normal gut flora, the cell density of C.
difficile is reduced and so the quorum signal produced does not reach the critical
concentration necessary to activate toxin synthesis. This may explain why C.
difficile do not cause disease as a commensal.
In conclusion, I have provided evidence demonstrating for the first time that
toxin synthesis in C. difficile is regulated by quorum signaling. This regulation is
independent of TcdC and mediated by the release of a small heat-stable factor that
accumulates during growth, and ultimately leads to activation of toxin synthesis. The
toxin-inducing factor was precipitated from the stationary phase culture supernatant
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fluid and partially purified by HPLC. Efforts are being made to identify this toxininducing factor, which would lead to understanding of the mechanism involved in
regulation of toxin synthesis in C. difficile. Such knowledge may lead to the
discovery of novel therapeutic targets that could be harnessed for the treatment of
both initial and recurrent C. difficile infections.
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